Introduction {#s1}
============

Maintenance of a correctly folded proteome is critical for cellular and organismal homeostasis. Consequently, all cells employ protein quality control to identify and eliminate misfolded proteins ([@bib47]). The wide diversity of proteins and the multitude of compartments in eukaryotic cells has driven the evolution of numerous quality control pathways for different classes of proteins and different types of errors. Thus, an important step in understanding the principles of cellular protein homeostasis is to delineate the recognition and degradation pathways for major classes of misfolded proteins.

Over 150 proteins in the human genome are anchored to the cell surface solely by a glycosylphosphatidylinositol (GPI) anchor in the membrane ([@bib44]). GPI-anchored proteins are ubiquitous across eukaryotes, often highly abundant, and have diverse roles including cell adhesion, signaling, intercellular communication, and enzymatic reactions ([@bib29]). How misfolded GPI-anchored proteins are selectively recognized and degraded remains poorly understood. The importance of this problem is highlighted by the capacity of mammalian prion protein (PrP), a widely expressed and conserved GPI-anchored protein, to cause neurodegenerative disease when misfolded variants accumulate in cells ([@bib34]).

The pathway used for degradation of a misfolded GPI-anchored protein depends on the step at which its biosynthesis fails. Errors in targeting GPI-anchored proteins to the endoplasmic reticulum (ER) or processing their signal for GPI anchor attachment at the membrane are handled by cytosolic ([@bib9]; [@bib26]) and ER-associated degradation (ERAD) pathways ([@bib1]; [@bib7]; [@bib40]; [@bib46]), respectively. Early studies in yeast suggested that once the GPI anchor is added, the misfolded protein is not degraded via Hrd1p ([@bib24]), a central ERAD factor that mediates ubiquitination and retrotranslocation of substrates from the ER to the cytosol ([@bib10]; [@bib12]; [@bib42]).

Instead, misfolded GPI-anchored proteins in yeast were suggested to use a seemingly unconventional pathway dependent on ER-to-Golgi transport ([@bib24]). Subsequent analysis suggested that ER export receptors of the TMED family (also known as the p24 family) rapidly sequester GPI-anchored proteins to prevent their engagement by Hrd1p, thereby allowing degradation in the vacuole ([@bib40]). The GPI-anchored protein was primarily degraded by ERAD when the TMED cargo receptor was eliminated. Thus, the primary pathway for GPI-anchored protein degradation in yeast is via trafficking to the vacuole, with ERAD serving as a failsafe pathway when the vacuole route is impaired.

Parallel studies in mammalian cells investigating mutant PrP degradation arrived at similar conclusions. First, investigation of the localization, trafficking, and turnover of a panel of human disease-causing PrP mutants showed that they are not degraded by ERAD, do not depend on the proteasome, and exit the ER despite their misfolding ([@bib8]). The misfolded population of mutant PrP was selectively observed in post-ER intracellular compartments *en route* to their ultimate degradation in acidic compartments presumed to be lysosomes. Using an artificial constitutively misfolded PrP mutant (termed PrP\*, containing a C179A mutation that cannot form the sole disulfide bond in PrP), trafficking from the ER to lysosomes was directly visualized by time-lapse imaging in live cells ([@bib37]). This study showed that PrP\* is primarily retained in the ER at steady state but can be released into the secretory pathway by acute ER stress.

The steps between ER retention and lysosomal clearance are only partially understood. Transit of PrP\* to the Golgi requires cargo receptor TMED10 (also known as Tmp21, or p24δ1) with which it interacts in co-immunoprecipitation experiments ([@bib37]). From here, the route to lysosomes is not established. At least a subpopulation was implicated in transiting the cell surface based on extracellular antibody uptake assays and trapping of PrP\* at the cell surface after cholesterol depletion ([@bib37]). The proportion of PrP\* using this itinerary was unclear but it is important to understand because exposing misfolded proteins to the extracellular environment can be detrimental. In the specific case of PrP, surface-exposed misfolded forms may facilitate uptake of prions into cells ([@bib22]).

From these combined studies in yeast and mammalian cells, it is thought that both folded and misfolded GPI-anchored proteins engage TMED family export receptors at the ER and traffic to the Golgi. At some step at or after the trans-Golgi network, their itineraries diverge. Folded GPI-anchored proteins go on to reside at the cell surface, whereas misfolded variants are delivered to the lysosome. It is not known how misfolded GPI-anchored proteins get from the Golgi to lysosomes, how they avoid aggregation during their journey through chaperone-poor post-ER compartments, or how cells discriminate folded from misfolded proteins to influence their trafficking. Here, we used quantitative flow cytometry and proteomic analyses to show that the majority of PrP\* traffics via the cell surface to lysosomes in a complex with resident ER chaperones and cargo receptors. This suggests that minor populations of abundant factors long thought to be restricted to the early secretory pathway have functional excursions to the cell surface during quality control of GPI-anchored proteins.

Results {#s2}
=======

Experimental system for quantitative analysis of PrP\* degradation {#s2-1}
------------------------------------------------------------------

To perform quantitative analysis of misfolded GPI-anchored protein degradation, we first generated and characterized a stable doxycycline-inducible HEK293T cell line expressing GFP-tagged PrP\* (GFP-PrP\*) integrated into a single defined locus in the genome. This mutant of PrP contains a Cys to Ala change at position 179, thereby preventing the formation of a critical disulfide bond required for PrP folding ([@bib37]). A matched cell line expressing wild type GFP-PrP from the same locus served as a control in these studies. Immunoblotting of total cell lysates after induction with doxycycline showed that the steady state level of GFP-PrP\* was very similar to GFP-PrP ([Figure 1A](#fig1){ref-type="fig"}). The different migration patterns are due to complex glycosylation of GFP-PrP during its transit through the Golgi in contrast to core-glycosylated GFP-PrP\* primarily retained in the ER.

![A stable-inducible cell line to study GPI-anchored protein quality control.\
(**A**) HEK293-TRex cells containing either GFP-PrP or GFP-PrP\* stably integrated at the same locus were induced to express the proteins with doxycycline for 48 hr prior to analysis by immunoblotting using anti-GFP antibody. Cultures without doxycycline induction were analyzed in parallel. Two exposures of the immunoblot are shown, along with a portion of the stained blot verifying equal loading. Unglycosylated ('no glyc."), core-glycosylated ('core'), and complex-glycosylated ('complex') species of GFP-PrP are indicated. (**B**) Cells expressing GFP-PrP or GFP-PrP\* were induced with doxycycline for 96 hr prior to analysis of GFP fluorescence by flow cytometry. The normalized histograms are shown. (**C**) Cells expressing GFP-PrP or GFP-PrP\* were induced for 48 hr with doxycycline, washed to remove doxycycline, then analyzed 24 hr later by fluorescent microscopy. Doxycycline withdrawal for 24 hr limited the amount of reporter mRNA in cells to relatively moderate levels, and was employed in most of the experiments in this study. This minimized over-expression artifacts and improved reproducibility. (**D**) Cells expressing GFP-PrP or GFP-PrP\* were treated with vehicle (DMSO) or the ER stressor thapsigargin (Tg, at 100 nM) for 3 hr in the presence of 100 µg/ml cycloheximide to suppress new protein synthesis. 250 nM bafilomycin A1 (BafA1) was included in one set of samples. Total GFP fluorescence was measured by flow cytometry. (**E**) Cells expressing GFP-PrP\* were treated with 100 nM thapsigargin (Tg) and 100 µg/ml cycloheximide and imaged at the indicated times.](elife-46740-fig1){#fig1}

Consistent with the immunoblotting, flow cytometry of GFP fluorescence showed that total GFP-PrP\* was almost identical to GFP-PrP ([Figure 1B](#fig1){ref-type="fig"}). As expected from earlier studies ([@bib37]), GFP-PrP\* was primarily localized intracellularly in a pattern consistent with the ER, while GFP-PrP was primarily at the cell surface ([Figure 1C](#fig1){ref-type="fig"}). Upon induction of acute ER stress with thapsigargin (Tg),\~80% of GFP-PrP\* was degraded after three hours ([Figure 1D](#fig1){ref-type="fig"}, upper panel). This degradation was almost completely inhibited by Bafilomycin A1 (BafA1), which prevents lysosome acidification and reduces proteolytic activity. By contrast, GFP-PrP was not affected by Tg and was only slightly stabilized by BafA1 ([Figure 1D](#fig1){ref-type="fig"}, lower panel) consistent with its slow turnover from the cell surface in lysosomes.

Microscopy of GFP-PrP\* cells at different times after ER stress showed re-localization from the ER to a peri-nuclear structure to cytosolic puncta before degradation ([Figure 1E](#fig1){ref-type="fig"}). Based on earlier work ([@bib37]), this corresponds to GFP-PrP\* trafficking via the Golgi to lysosomes. While Brefeldin A (BFA) causes ER retention of GFP-PrP\* and precludes trafficking to lysosomes (as verified by microscopy; data not shown), degradation still proceeds, albeit somewhat less efficiently ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Based on earlier studies in yeast ([@bib40]), it is likely that in the absence of ER export, GFP-PrP\* is eventually degraded by ERAD. Thus, our matched stable-inducible cell lines recapitulate the previously described stress-triggered PrP\* degradation in lysosomes and the comparatively stable cell surface residence of PrP. These tools provided the foundation for quantitative analyses of PrP\* quality control, trafficking, and degradation.

Detection and quantification of PrP\* at the cell surface {#s2-2}
---------------------------------------------------------

To monitor GFP-PrP at the cell surface, we prepared purified recombinant anti-GFP camelid-derived nanobody (Nb) labeled with a chemical fluorophore and 3X-FLAG epitope as an affinity handle. The Nb-FLAG probe is small (\~18 kD), monovalent, exceptionally specific, has sub-nM affinity, very fast on-rate, and very slow off-rate. These properties make it an ideal probe for detecting but not crosslinking surface-exposed GFP. Titration experiments showed that extracellular Nb concentrations above 10 nM saturate surface labeling of GFP-PrP ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Using saturating concentrations of extracellular Nb, we found that cells expressing GFP-PrP\* contain a clearly detectable surface population whose level is between one-twentieth and one-fiftieth of cells expressing GFP-PrP ([Figure 2A](#fig2){ref-type="fig"}).

![Misfolded PrP is detectable at the cell surface prior to lysosomal degradation.\
(**A**) Cells expressing GFP-PrP and GFP-PrP\* were incubated on ice with 200 nM extracellular Alexa647-conjugated Nb and Alexa647 fluorescence was measured by flow cytometry. Uninduced cells were analyzed in parallel and are shown in gray. (**B**) Diagram of experimental strategy to compare relative surface levels of GFP-PrP\* and GFP-PrP. (**C**) Cells expressing GFP-PrP and GFP-PrP\* were labeled with saturating amounts of anti-GFP Nb on ice, washed, and lysed under denaturing (SDS) or non-denaturing (CHAPS) conditions. Bound Nb was analyzed by immunoblotting relative to serial dilutions of purified recombinant Nb. (**D**) The indicated relative amounts of surface-derived complexes purified under non-denaturing conditions were analyzed by immunoblotting for GFP and FLAG. (**E**) GFP-PrP\*-expressing cells treated for 96 hr with control or AP2-targeting siRNAs were surface-labeled with Alexa647-Nb and analyzed by flow cytometry. HEK293T cells without GFP-PrP\* were analyzed for comparison (gray). (**F**) GFP-PrP\*-expressing cells were transiently transfected with FusionRed-Dynamin S45N ([@bib2]) or empty vector for 24 hr prior to surface staining with Alexa647-Nb and analysis by flow cytometry. (**G**) GFP-PrP\*-expressing cells were treated with 2.5 µg/ml Brefeldin A (BFA) for two hours prior to surface staining with Alexa647-Nb and analysis by flow cytometry.](elife-46740-fig2){#fig2}

To quantify this minor surface population, we compared the amount of surface-bound Nb to serial dilutions of purified Nb ([Figure 2B and C](#fig2){ref-type="fig"}). As expected, cells that did not express GFP-PrP\* or GFP-PrP did not yield appreciable Nb. Cells expressing GFP-PrP\* yielded one-twentieth the amount of Nb relative to cells expressing GFP-PrP (50 pg and 1 ng, respectively). When the surface-bound Nb was purified under non-denaturing conditions, GFP-PrP\* was co-precipitated as expected ([Figure 2D](#fig2){ref-type="fig"}). Consistent with the above quantification, analysis of Nb-bound GFP-PrP\* relative to 5% of Nb-bound GFP-PrP showed equal amounts of GFP signal by immunoblotting ([Figure 2D](#fig2){ref-type="fig"}). Importantly, control experiments in which lysate from Nb-labeled cells was mixed with lysates containing free GFP showed that free GFP was not recovered in the Nb-purified complexes ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). This verified that surface-bound Nb does not exchange antigens after cell lysis over the time frame needed for affinity purification of Nb-antigen complexes. Thus, 20-fold more PrP resides at the cell surface than PrP\*.

Based on sensitivity to extracellular trypsin, we could determine that 87% of total GFP-PrP is at the cell surface ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Given that total GFP-PrP\* is equal to total GFP-PrP ([Figure 1A--1C](#fig1){ref-type="fig"}), we can deduce that \~4.4% of GFP-PrP\* is at the cell surface (i.e., one-twentieth of 87%). Most of the remaining 96% of GFP-PrP\* is located in the ER ([Figure 1C](#fig1){ref-type="fig"}). Despite this very low steady state level at the surface, two additional experiments validated its existence. First, the surface level increased when endocytosis was impaired by either knocking down AP2 ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}) or expressing a dominant-negative Dynamin ([@bib19]) ([Figure 2F](#fig2){ref-type="fig"}). Second, the surface population was decreased to near-background levels by blocking ER exit with BFA for two hours ([Figure 2G](#fig2){ref-type="fig"}). Thus, by both flow cytometry and direct affinity purification,\~4.4% of GFP-PrP\* is at the cell surface at steady state. This population is apparently transient since it is lost shortly after further ER-to-surface trafficking is blocked ([Figure 2G](#fig2){ref-type="fig"}). Curiously, almost all of the surface population of GFP-PrP\* contains immature glycans ([Figure 2D](#fig2){ref-type="fig"}) despite having trafficked through the Golgi (see Discussion).

Nearly all PrP\* transits the cell surface during its degradation {#s2-3}
-----------------------------------------------------------------

The ability to increase and decrease the surface population of GFP-PrP\* by manipulating trafficking pathways provides qualitative evidence that it is constantly delivered to and degraded from the plasma membrane. However, the numerous pleiotropic consequences of inhibiting major trafficking pathways preclude this strategy for deducing the proportion of total synthesized GFP-PrP\* accessing the surface. We therefore sought to estimate GFP-PrP\* flux through the cell surface in trafficking-competent cells. The strategy we used was to directly measure the total amount of extracellular Nb taken up by cells during a time period when the entire ER pool of GFP-PrP\* traffics to lysosomes ([Figure 3A](#fig3){ref-type="fig"}, top diagram). This value was compared to a fluorescence standard generated in parallel by surface-stained GFP-PrP cells using the same Nb ([Figure 3A](#fig3){ref-type="fig"}, bottom diagram).

![The majority of misfolded PrP transits the cell surface en route to lysosomes.\
(**A**) Experimental strategy to measure GFP-PrP\* transit through the cell surface (top) relative to a known standard generated by saturating surface labeling of GFP-PrP cells. (**B**) Cells expressing GFP-PrP\* were incubated for 3 hr at 37°C with 100 nM Tg and 10 nM extracellular Alexa546-Nb prior to washing and analysis by flow cytometry. This sample was compared to GFP-PrP cells surface-labeled with Alexa546-Nb. (**C**) GFP-PrP\*-expressing cells and uninduced controls were incubated for various times in the presence of 10 nM Alexa546-Nb in the culture medium. Half the cells contained 100 nM thapsigargin (Tg) while the other half were untreated. The cells at each time point were analyzed by flow cytometry. The graph depicts the median fluorescence intensity of internalized nanobody relative to time 0. (**D**) Wild type (WT) and TMED10 knockout (KO) cells expressing GFP-PrP\* were allowed to internalize Alexa647-Nb from the extracellular medium for 2 hr during treatment with 100 nM thapsigargin. Fluorescent Nb levels were measured by flow cytometry. KO cells transiently transfected with HA-tagged TMED10 (rescue) were analyzed in parallel. (**E**) The amount of extracellular Nb uptake was measured over the course of 2 hr in unstressed cells expressing GFP-PrP\*. Wild type (WT) cells were compared to TMED10 knockout cells (KO). Cells lacking GFP-PrP\* (HEK) were analyzed as a negative control. (**F**) GFP-PrP-expressing cells were treated with 1 µM Brefeldin A (BFA) for 2.5 hr to retain GFP-PrP in the ER. The media was then changed to remove BFA while adding Alexa647-Nb, and incubated for 2 hr before analysis by flow cytometry.](elife-46740-fig3){#fig3}

Based on direct imaging ([Figure 1E](#fig1){ref-type="fig"}) and the time point when most PrP\* is degraded in lysosomes ([Figure 1D](#fig1){ref-type="fig"}), we decided to monitor Nb uptake during an acute 3 hr ER stress treatment of GFP-PrP\* cells. Due to a combination of transcriptional shutoff prior to the experiment and translation attenuation during acute ER stress, new GFP-PrP\* synthesis during the time course is relatively minor compared to the pre-existing population. Furthermore, we verified in preliminary experiments that uptake in the absence of GFP-PrP\* expression is negligible over 3 hr without or with ER stress (data not shown; see also [Figure 3B](#fig3){ref-type="fig"}, gray trace). Finally, we confirmed that the fluorophore on the Nb remains quantitatively fluorescent and intracellular for at least 3 hr after uptake even if GFP-PrP\* and the Nb are being degraded in lysosomes ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These considerations allow us to assign essentially all nanobody uptake during the time course to GFP-PrP\* having accessed extracellular anti-GFP nanobody.

GFP-PrP\* cells at steady state, as characterized in [Figure 1](#fig1){ref-type="fig"}, were treated for 3 hr with acute ER stress (0.1 µM thapsigargin) in the presence of extracellular fluorescent Nb. The cells were then washed and the total amount of nanobody uptake was quantified by flow cytometry relative to the Nb-labeled GFP-PrP fluorescence standard. We observed that the nanobody taken into GFP-PrP\* cells ([Figure 3B](#fig3){ref-type="fig"}, red trace) slightly exceeded the GFP-PrP fluorescence standard ([Figure 3B](#fig3){ref-type="fig"}, blue trace). The fluorescence standard represents the quantity of nanobody binding that corresponds to 87% of total GFP-PrP. At the start of the experiment, the amount of GFP-PrP\* available for nanobody binding is \~4.4% (i.e., 20-fold less than our fluorescence standard). Thus, for GFP-PrP\* cells to accumulate an amount of nanobody comparable to the fluorescence standard,\~86% of the intracellular population would need to access and trap extracellular nanobody. Given that Nb accumulation in GFP-PrP\* cells actually exceeds the GFP-PrP standard ([Figure 3B](#fig3){ref-type="fig"}), we conclude that the vast majority of initially intracellular GFP-PrP\* must access the cell surface on its way to lysosomes during stress-triggered degradation. As expected for a trafficking itinerary via the Golgi, Nb uptake displayed a lag of \~30 min consistent with the transit time for GFP-PrP\* from the ER to the cell surface ([Figure 3C](#fig3){ref-type="fig"}).

In the absence of ER stress, GFP-PrP\* cells also take up extracellular nanobody selectively when GFP-PrP\* is expressed ([Figure 3C](#fig3){ref-type="fig"}). This suggests that even at steady state, GFP-PrP\* accesses the cell surface similarly to what is observed during stress. The slopes of the uptake time courses between 30 and 90 min suggest that the rate of surface access is \~6 fold higher during acute ER stress than at steady state. The basis of this difference is likely due to the different rates of ER egress under unstressed and stressed conditions. This result suggested the possibility that GFP-PrP\* degradation during acute stress is an accelerated version of the degradation pathway under normal conditions.

To investigate this idea, we tested whether TMED10, previously implicated in stress-triggered PrP\* export from the ER ([@bib37]; [@bib40]), is similarly required under unstressed conditions. In preliminary studies, we found that acute knockdown of TMED10 ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) impaired uptake of extracellular Nb ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), an indicator of reduced GFP-PrP\* flux through the cell surface. Gene editing was then used to knock out TMED10 in GFP-PrP\* cells ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Fluorescence microscopy showed that in ∆TMED10 cells, acute ER stress no longer caused GFP-PrP\* egress from the ER ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) and sharply impaired uptake of extracellular Nb ([Figure 3D](#fig3){ref-type="fig"}). Using the uptake assay, we found that Nb accumulation was also impaired under non-stressed conditions, further suggesting that the same pathway is used, albeit at a lower rate ([Figure 3E](#fig3){ref-type="fig"}). Importantly, little or no effect was observed on the amount of GFP-PrP trafficked to the cell surface in ∆TMED10 cells ([Figure 3F](#fig3){ref-type="fig"}) indicating that neither trafficking nor GPI-anchored protein biogenesis are appreciably impaired. Thus, although both PrP\* and PrP interact with TMED10 by coimmunoprecipitation ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}), only PrP\* strongly relies on it for lysosomal degradation via the cell surface.

A complex of p24 proteins is required for PrP\* trafficking and degradation {#s2-4}
---------------------------------------------------------------------------

TMED10 sedimentation through a sucrose gradient suggests a native size larger than its 24 kD molecular weight ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), consistent with it being part of a multi-protein complex ([@bib28]). Earlier work suggested that the coiled-coil region of the TMED family is important for homo- and hetero-typic interactions ([@bib16]; [@bib21]). To test whether the role of TMED10 in GFP-PrP\* degradation depends on complex formation, we assessed the ability of an assembly mutant lacking the coiled-coil (∆CC) to rescue the phenotype of ∆TMED10 cells. While ∆TMED10 cells rescued with wild type TMED10 largely recovered Nb uptake by GFP-PrP\* ([Figure 3D](#fig3){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), ∆CC was completely inactive ([Figure 4A](#fig4){ref-type="fig"}) despite unimpaired interaction with GFP-PrP\* ([Figure 4B](#fig4){ref-type="fig"}). Of note, deletion of the lumenal GOLD domain implicated in protein-protein interactions of uncertain relevance was functional in restoring GFP-PrP\* trafficking to ∆TMED10 cells (data not shown) and unimpaired in its interaction with GFP-PrP\* ([Figure 4B](#fig4){ref-type="fig"}). These observations can be explained if GFP-PrP\* trafficking relies on a complex of multiple homologous TMED family proteins, more than one of which can interact with GFP-PrP\*. The precise identity of the cargo receptor complex employed by GFP-PrP\* and the nature of its selective engagement of misfolded GPI-anchored proteins remains to be defined.

![A complex of several TMED proteins facilitates GFP-PrP\* degradation.\
(**A**) Wild type (WT) or TMED10 knockout (KO) cells expressing GFP-PrP\* were assayed for thapsigargin-stimulated extracellular Nb uptake as in [Figure 3D](#fig3){ref-type="fig"}. In addition, the KO cells were transiently transfected with HA-tagged TMED10 lacking its coiled-coil domain (∆CC) and the transfected cells were analyzed in parallel. (**B**) RFP-tagged wild type (WT) TMED10, or constructs lacking the GOLD domain (residues 41--129; ∆GOLD) or coiled-coil domain (residues 130--183; ∆CC) were transiently transfected into ∆TMED10 cells inducibly expressing GFP-PrP\*. GFP-PrP\* was either left uninduced or induced for 48 hr prior to analysis. GFP-PrP\* was immunoprecipitated using sepharose-conjugated anti-GFP Nb and analyzed by immunoblotting for GFP and RFP relative to input lysates. All input samples are from the same blot and exposure, with the vertical line indicating where intervening lanes were removed. All of the IP samples are also from the same blot and exposure. (**C**) Wild type or TMED10 knockout cells were transiently transfected with RFP-tagged WT or ∆CC TMED10. Two days post-transfection, cells containing moderate levels of RFP were isolated by flow cytometry, lysed, and immunoblotted against TMED2.](elife-46740-fig4){#fig4}

Consistent with TMED10 interacting with other TMED family member(s), ∆TMED10 cells had reduced levels of TMED2, a putative part of the complex ([Figure 4C](#fig4){ref-type="fig"}). Reduced TMED2 is partially restored upon acute re-introduction of TMED10 by transient transfection, but not by re-introduction of the ∆CC mutant defective in hetero-typic TMED family interactions. Notably, the phenotype of ∆TMED10 cells cannot be rescued by TMED2 over-expression arguing against TMED2 loss as the sole basis of impaired GFP-PrP\* trafficking ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Analysis of Nb uptake by GFP-PrP\* in cells treated with siRNAs against each TMED family member suggests that in addition to TMED10, TMED2 is strongly required ([Figure 4---figure supplement 1D,E](#fig4s1){ref-type="fig"}). A weaker phenotype is observed with at least one siRNA for both TMED5 and TMED9, but not TMED7. The combination of TMED2/5/9/10 was previously reported to participate in the ER exit of GPI-anchored proteins ([@bib25]). Our findings suggest that GFP-PrP\* trafficking similarly requires TMED2 and TMED10, possibly in a complex that also includes TMED5 and TMED9. A systematic analysis of the complete cargo receptor complex for misfolded GPI-anchored proteins requires further study.

The PrP\* interactome during ER-to-lysosome trafficking {#s2-5}
-------------------------------------------------------

The data thus far have established that GFP-PrP\* constitutively (but slowly) leaves the ER in a TMED10-dependent manner and traffics via the cell surface to lysosomes. By contrast, GFP-PrP efficiently folds, leaves the ER, and resides primarily at the plasma membrane from where it slowly turns over in lysosomes. To understand the basis of these different itineraries, we systematically analyzed PrP\*-specific interactions in both the ER and post-ER compartments.

Using the GFP tag as an affinity handle, we first purified GFP-PrP and GFP-PrP\* from non-stressed cells at steady state and compared their interaction partners. As observed in two examples ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), GFP-PrP\* specifically co-precipitated a variety of proteins that were reduced or absent from cells expressing GFP-PrP. As expected for a misfolding mutant, mass spectrometry identified a number of ER-resident chaperones that were co-precipitated preferentially with GFP-PrP\*. The most abundant of these were Calnexin (CNX) and BiP (also called GRP78), with lesser amounts of GRP94 (also called endoplasmin), protein disulphide isomerase (PDI), ERP57 (an oxidoredutase that cooperates with CNX), and ERP72. A wide range of other interaction partners were recovered with GFP-PrP\* at lower levels, but their specificity and relevance were less obvious.

![Proteomic analysis of PrP\* interactions during its trafficking to lysosomes.\
(**A**) Cells expressing GFP-PrP and GFP-PrP\* were lysed under non-denaturing conditions, affinity purified via immobilized anti-GFP Nb, separated by SDS-PAGE, and stained with SYPRO-Ruby. The positions of key proteins (verified by mass spectrometry) are shown. (**B**) GFP-PrP\* from wild type and ∆TMED10 cells was affinity purified under non-denaturing conditions, separated by SDS-PAGE, and stained with SYPRO-Ruby. The asterisk indicates the only band obviously absent in the ∆TMED10 sample, presumably corresponding to TMED10 itself. (**C**) GFP-PrP\* was immunoprecipitated from wild type (WT) and ∆TMED10 (KO) cells as in panel B and analyzed by quantitative mass spectrometry. The x-axis orders proteins by relative abundance in the immunoprecipitation (one being the most abundant), and the y-axis plots the Log~2~ value of the WT/KO ratio of abundances. Proteins whose Log~2~ ratios are \>0.5 in all three independent experiments are highlighted in red, and those \>0.5 in 2 of 3 independent experiments are highlighted in blue. (**D**) GFP-PrP\* was immunoprecipitated as in panel B from wild type (WT) and ∆TMED10 (KO) cells at different times after thapsigargin-induced acute ER stress. HEK293T cells lacking GFP-PrP\* were used as a specificity control (HEK). The positions of several abundant proteins identified by mass spectrometry are indicated. The portion of the gel showing the TMED family members is also shown at higher contrast. All eight IP samples (not including the HEK control) were subjected to quantitative tandem mass tagging (TMT) mass spectrometry ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). (**E**) The quantitative mass spectrometry results from the '0' time point and the '60 min' time point from the experiment in panel D are plotted as Log~2~ values of the WT/KO ratio. Various proteins discussed in the text are indicated. (**F**) GFP-PrP and GFP-PrP\* were immunoprecipitated under non-denaturing conditions following thapsigargin-induced ER stress for the indicated time periods. Input and immunoprecipitated samples were separated by SDS-PAGE and analyzed by immunoblotting against CNX, TMED10, and GFP.\
10.7554/eLife.46740.012Figure 5---source data 1.Complete tandem mass tagging mass spectrometry data.The eight samples corresponding to the four time points each for WT and ∆TMED10 cells from [Figure 5D](#fig5){ref-type="fig"} were analyzed by tandem mass tagging (TMT) quantitative proteomics and the data tabulated in the Excel table. Each tab of the Excel table illustrates the sequential steps in the normalization and analysis of the raw data, ending in the graph depicted in [Figure 5E](#fig5){ref-type="fig"}.](elife-46740-fig5){#fig5}

To determine which (if any) of these other potential interacting partners might engage PrP\* after it leaves the ER, we performed a quantitative mass spectrometry analysis of PrP\*-interacting proteins from wild type and ∆TMED10 cells. We reasoned that the impaired ER exit of PrP\* in ∆TMED10 cells would preclude biologically relevant post-ER interactions, whereas ER-resident interactors (or those recovered solely due to the 'sticky' nature of PrP\*) would be unchanged. As expected, the stained gel shows that the major interactors (i.e., with resident ER chaperones) are essentially unchanged ([Figure 5B](#fig5){ref-type="fig"}), consistent with the principal location of PrP\* in the ER in both cases. A conspicuous band between 17 kD and 25 kD, corresponding to the size of most TMED family members, was specifically absent in the ∆TMED10 sample.

Direct and quantitative comparison of the two samples by tandem-mass-tag (TMT) mass spectrometry from three independent biological replicates identified between \~1400 and\~2000 proteins ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}, and data not shown). For each of these, the relative amount recovered with GFP-PrP\* from wild type (WT) cells versus ∆TMED10 cells (KO) was calculated (i.e., the WT/KO ratio, normalized so that the PrP ratio is 1, displayed as a Log~2~ value). Ten proteins showed a WT/KO ratio of least 1.4 (i.e., Log~2~ of 0.5) from all three TMT experiments, and another 11 proteins exceeded this threshold in two of three experiments (six were found in the experiment displayed in [Figure 5C](#fig5){ref-type="fig"}). Of these 21 proteins, seven were TMED family members involved in bidirectional trafficking between the ER and Golgi. Notably, the four family members implicated in functional assays of GFP-PrP\* trafficking (TMED10, TMED2, TMED5, and TMED9) were among the proteins enriched in wild type cells in all three TMT experiments. This can be explained by lower TMED family abundance and/or reduced interaction with PrP\* in ∆TMED10 cells.

Very few other post-ER components of the secretory or endocytic pathways showed a WT/KO ratio above 1.4. Two homologous lectins involved in ER-Golgi protein trafficking (VIP36 and VIP36L) and a putative secreted calcium binding protein (Stannocalcin2) of unclear function were the only proteins within the secretory pathway that could realistically encounter PrP\* in post-ER compartments. Some components such as Sec22A, GM130 (also called GOLGA2), or GRASP55 (also called GORASP2) might interact indirectly via the TMED cargo receptors or the trafficking lectins, while the remaining proteins with elevated WT/KO ratios are likely to be artefacts. Notably, no cell surface or endosomal membrane proteins were found that could represent interacting partners during the post-Golgi steps of PrP\*'s trafficking itinerary to lysosomes.

To specifically enrich for such post-ER interactors, we analyzed GFP-PrP\* interactors using TMT mass spectrometry from wild type and ∆TMED10 cells at different times after acute ER stress. GFP-PrP\* leaves the ER rapidly after stress, is preferentially enriched in Golgi and post-Golgi compartments at 30--60 min, and degraded beginning shortly after 60 min ([Figure 1E](#fig1){ref-type="fig"}). These post-ER locations are effectively inaccessible to GFP-PrP\* in ∆TMED10 cells even after stress ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}), providing a specificity control for any post-ER interaction partners. Conversely, we expected resident ER interactors to be preferentially lost after stress in wild type cells but not in ∆TMED10 cells. Strikingly, the interaction profiles on the stained gels from two independent replicates were essentially unchanged across time points or between wild type versus ∆TMED10 cells ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Only a \~ 24 kD band matching the size of TMED family members was absent from purifications using ∆TMED10 cells.

Of the 2132 proteins represented in the TMT mass spectrometry analysis, very few differed between wild type and ∆TMED10 cells at any of the time points after stress ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), beyond those already discussed above (e.g., compare [Figure 5C and E](#fig5){ref-type="fig"}). An important point of comparison is the interactome after 60 min of ER stress, when GFP-PrP\* resides entirely in Golgi and post-Golgi compartments in wild type cells ([Figure 1E](#fig1){ref-type="fig"}) but entirely in the ER in ∆TMED10 cells ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Strikingly, the WT/KO ratios for nearly all GFP-PrP\* interactors were very similar before (x-axis) versus after (y-axis) 60 min of ER stress ([Figure 5E](#fig5){ref-type="fig"}). Only three proteins showed a high WT/KO ratio preferentially after ER stress: SEP15, PRPF6, and UNC45A. However, two of these (PRPF6 and UNC45A) are nuclear proteins, while the third (SEP15) is a resident ER protein. Thus, none of these are realistic PrP\* interactors in the post-ER compartments where PrP\* is observed after stress. Furthermore, the differences for PRPF6 and UNC45A are not observed at either 30 or 120 min time points ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), suggesting they are one-off artefacts. The increased WT/KO ratio for SEP15 appears to be due to preferential loss in the KO sample, not an enhanced interaction in WT cells. Thus, no plausible stress-induced post-ER GFP-PrP\* interactions could be detected at any time point.

There was an equally striking paucity of interactors that were preferentially reduced or lost upon ER stress in WT cells ([Figure 5E](#fig5){ref-type="fig"}). Interacting proteins with reduced WT/KO ratios selectively after stress were either histones, the secreted protein Dermcidin, or the ER-resident protein BiP. Of these, only BiP would seem to be a bona fide interactor and its reduced interaction after acute ER stress preferentially in WT cells is consistent with egress of GFP-PrP\* from the ER. However, the reduction was only \~50% despite essentially all GFP-PrP\* leaving the ER. Furthermore, other well-validated GFP-PrP\* interactors in the ER such as CNX or the TMED family did not show stress-induced reductions in WT/KO ratios that would be expected when GFP-PrP\* leaves the ER. These data collectively suggested that the interactome of PrP\* is remarkably unchanged during either its constitutive or stress-induced trafficking from the ER to lysosomes via the cell surface.

To investigate this idea more directly, we analyzed both CNX and TMED10 interactions with GFP-PrP\* before and after acute ER stress over a 180 min time course. Consistent with the TMT mass spectrometry results, GFP-PrP\* associated with both CNX and TMED10 over the entire 180 min time course ([Figure 5F](#fig5){ref-type="fig"}). The amount that was associated was completely unchanged for 60 min. Although a reduction in CNX and TMED10 were observed at 180 min, this mirrored the reduced level of GFP-PrP\* at this time point due to its lysosomal degradation. By contrast, GFP-PrP only transiently and weakly associated with CNX at the first time point (before ER stress), consistent with its release upon folding and egress to the cell surface. The TMED10 interaction with GFP-PrP declined more slowly as expected for a cargo receptor that accompanies its substrate to at least the Golgi. These results validate the mass spectrometry findings and show that GFP-PrP\* retains its associations with factors of the early secretory pathway throughout its trafficking itinerary to the lysosome.

Persistent CNX interaction with PrP\* after induction of ER stress was particularly surprising given the earlier finding that this interaction is lost when PrP\* exits the ER during stress ([@bib37]). We believe this discrepancy might be attributed to the different cell types used in the earlier and present studies showing different kinetics of PrP\* degradation. It appears that degradation proceeds more rapidly in the cells analyzed previously than the experimental system used here. It may therefore be that at the 30 min time point examined in the earlier study, PrP\* was already partially in acidic compartments and being degraded, analogous to the 180 min time point of our experiment. Regardless of the exact reason, our analysis of the PrP\* interactome at multiple time points using both quantitative proteomics and direct visualization of interacting partners on stained gels argues strongly that PrP\* retains the interactions it makes in the ER at later points during its trafficking.

Resident ER proteins are associated with cell surface PrP\* {#s2-6}
-----------------------------------------------------------

A major implication of the results in [Figure 5](#fig5){ref-type="fig"} is the entirely unexpected conclusion that GFP-PrP\* is associated with normally intracellular resident ER proteins when it arrives at the cell surface. We designed experiments to directly evaluate this idea. Using the ability to selectively tag the minor cell surface population of GFP-PrP\* with the tightly binding anti-GFP Nb ([Figure 2B](#fig2){ref-type="fig"}), we first evaluated whether surface GFP-PrP\* was in larger molecular weight complexes by sucrose gradient sedimentation. As expected from its chaperone interactions in the ER, GFP-PrP\* in total lysate migrated far more heterogeneously than GFP-PrP ([Figure 6A](#fig6){ref-type="fig"}, top panels): whereas GFP-PrP was primarily in fractions 3--5, substantial amounts of GFP-PrP\* were distributed across fractions 6--10 (fraction 11 represents non-solubilized material). Similarly, the distribution of cell surface GFP-PrP\* was more heterogeneous than cell surface GFP-PrP ([Figure 6A](#fig6){ref-type="fig"}, bottom panels). For example, relatively less GFP-PrP\* was seen in fractions 3--5 (where the majority of GFP-PrP was observed), while relatively more GFP-PrP\* was seen in fractions 6--10. This difference hinted at the possibility that GFP-PrP\* at the cell surface is in protein complex(es) that differ from the mostly uncomplexed GFP-PrP.

![Cell surface PrP\* is associated with ER-derived factors.\
(**A**) Cells expressing GFP-PrP and GFP-PrP\* were labeled on ice with saturating levels of extracellular Nb-FLAG, lysed under non-denaturing conditions, and separated by size on a 5--25% sucrose gradient. Fractions were immunoblotted with anti-GFP to detect total cellular GFP-PrP and GFP-PrP\*, and anti-FLAG to detect surface-localized Nb complexes. Size standards are estimates based on migration of known proteins on such gradients, which migrate reproducibly from experiment to experiment. (**B**) GFP-PrP\*-expressing cells and control HEK293T cells were surface labeled and lysed as in panel A and affinity purified via the FLAG epitope tag on the Nb. Elutions were separated by SDS-PAGE and stained with SYPRO-Ruby, with key proteins indicated on the right. (**C**) Cells expressing GFP-PrP and GFP-PrP\* were surface labeled such that equal amounts of anti-GFP Nb-FLAG coated the surface of these two cells. This was accomplished by using saturating (200 nM) Nb for GFP-PrP\* cells and 2 nM Nb for GFP-PrP cells. These values were determined in preliminary titration experiments. Surface-localized GFP-PrP and GFP-PrP\* were then affinity purified as in panel B, the samples were separated by SDS-PAGE, and subjected to immunoblotting as indicated. The right panel verifies that equal amounts of GFP-PrP and GFP-PrP\* were recovered with the Nb in the immunoprecipitates. (**D**) Schematic of the strategy to selectively label proteins near the cell surface population of GFP-PrP\* using recombinant anti-GFP Nb-APEX2. Biotinylated proteins are recovered by streptavidin pulldown. (**E**) Cells expressing GFP-PrP and GFP-PrP\* were surface labeled such that equal amounts of anti-GFP Nb-APEX2 coated the surface of these two cells, with saturating (200 nM) Nb for GFP-PrP\* cells and 0.5 nM Nb for GFP-PrP cells. These values were determined in preliminary titration experiments. After 1 min of biotinylation and quenching, the cells were lysed and the input samples and streptavidin-recovered products were analyzed by immunoblotting.](elife-46740-fig6){#fig6}

Using an affinity tag on the Nb, we selectively purified the surface population of GFP-PrP\* after first washing away all excess extracellular Nb. For comparison, we performed the same experiment with GFP-PrP. Lysis conditions were chosen such that GFP-PrP\* is efficiently solubilized ([Figure 2C](#fig2){ref-type="fig"}) while still maintaining both Nb-GFP interactions ([Figure 2D](#fig2){ref-type="fig"}) and putative PrP\* interactions ([Figure 6A](#fig6){ref-type="fig"}). Sucrose gradient analysis of the eluates from these surface-specific purifications showed that GFP-PrP migrates as an uncomplexed protein without any appreciable co-purifying proteins ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). By contrast, GFP-PrP\* co-purified with proteins of \~75 and 90 kD that were identified by mass spectrometry and immunoblotting as BiP and CNX, respectively ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). These proteins seemed to migrate in somewhat different fractions suggesting that they were either in separate complexes with GFP-PrP\* or might have dissociated during elution or gradient fractionation.

Multiple independent large-scale surface purifications of cell surface GFP-PrP\* were analyzed by mass spectrometry and verified to contain BiP, CNX, TMED family members, and lesser amounts of other ER-resident chaperones like GRP94 ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). These surface interactions were validated by immunoblotting to be specific for GFP-PrP\* when compared with equal amounts of GFP-PrP purified selectively from the surface ([Figure 6C](#fig6){ref-type="fig"}). Separate experiments ensured that the Nb does not dissociate from GFP-PrP\* and rebind intracellular GFP-PrP\* molecules after lysis ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), consistent with the Nb's extremely slow off rate from GFP. Furthermore, post-lysis mixing with a radiolabeled cell lysate did not recover any radiolabeled proteins selectively in the samples containing Nb-GFP-PrP\* complexes ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). This argues against chaperone interactions with surface GFP-PrP\* occurring after lysis.

Quantification relative to serial dilutions of total lysate indicates that \~ 0.1% of total CNX was recovered with surface GFP-PrP\* ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Given a purification efficiency of \~20% and the fact that \~ 4.4% of all GFP-PrP\* is on the surface, we can estimate that \~ 0.9% of total cellular GFP-PrP\* is recovered in the experiment. Because CNX is a very abundant protein, recovery of \~0.1% of total cellular CNX with \~0.9% of total GFP-PrP\* would make them of comparable abundance in the purified complex, consistent with what is observed on stained gels. GFP-PrP\* is also associated with other abundant chaperones and cargo receptors at similar or somewhat lower levels; hence, the sum of these interactors would be comparable to the abundance of surface GFP-PrP\*. This would be consistent with the conclusion from time-resolved mass spectrometry results ([Figure 5E](#fig5){ref-type="fig"}) that GFP-PrP\*'s interactome in post-ER compartments is essentially unchanged from its ER interactome.

As a final orthogonal test of the idea that surface GFP-PrP\* retains its intracellular interaction partners, we used a selective enzymatic labeling strategy to biotinylate GFP-PrP\* neighbors on intact live cells ([@bib30]; [@bib36]). We prepared a recombinant Nb fusion with the peroxidase APEX2 and used purified Nb-APEX2 to selectively decorate the surface population of GFP-PrP\* or GFP-PrP. When the APEX substrate biotin-phenol is added to the extracellular medium, it is converted by APEX2 to a highly reactive membrane-impermeable intermediate that biotinylates nearby proteins ([Figure 6D](#fig6){ref-type="fig"}). Preliminary experiments using GFP-PrP cells identified the minimum saturating concentrations of Nb-APEX and showed that proximity labeling could be achieved within 1 min ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). Importantly, quenching conditions were identified after which no detectable labeling could be observed ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}).

After decorating GFP-PrP\* cells with Nb-APEX2, removing the excess, labeling with biotin-phenol for 1 min, and quenching, the biotinylated proteins were recovered via immobilized streptavidin. CNX was recovered as detected by immunoblotting ([Figure 6E](#fig6){ref-type="fig"}). When GFP-PrP cells were treated in an identical manner under conditions of equal Nb-APEX2 surface density ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}), CNX was not effectively recovered in the streptavidin pulldowns ([Figure 6E](#fig6){ref-type="fig"}). Thus, in live and intact cells, surface GFP-PrP\* is selectively adjacent to CNX, which has apparently accompanied it from the ER on the way to lysosomes.

Acute misfolding at the cell surface does not trigger degradation {#s2-7}
-----------------------------------------------------------------

The sustained interaction with intracellular factors during its trafficking itinerary, together with the apparent lack of any new interactions at post-Golgi compartments, suggested the hypothesis that the intracellular factors are a critical cue for PrP\*'s rapid removal from the cell surface. In this model, both PrP and PrP\* arrive at the cell surface, but one or more of the factors PrP\* has retained from inside the cell triggers its endocytosis and lysosomal degradation. The large number of factors, their critical roles in intracellular homeostasis and trafficking, and the likelihood of pleiotropic consequences upon their disruption posed major challenges to testing this idea. For example, deleting TMED10 precludes ER exit of PrP\*, preventing a straightforward test of whether it has a crucial role in PrP\* endocytosis.

To circumvent these obstacles, we designed a generic strategy to test the functional importance of retained intracellular interaction partners for rapid removal of misfolded GPI-anchored proteins from the cell surface. We reasoned that if these factors are important at the surface, then acute misfolding of a GPI-anchored protein only after it had reached the surface should preclude its recognition and endocytosis. By contrast, if a separate surface surveillance system (which has eluded our proteomic searches) is instead critical, then acute misfolding would be recognized regardless of the absence of retained intracellular factors. Our approach to test this idea relied on the observation that the folded state of a mutant FKBP12 (hereafter simply FKBP\*) is stabilized by a bound ligand called Shield1 ([@bib11]; [@bib20]). We could then allow the GPI-anchored FKBP\* reporter to reach the surface of cells grown in the presence of Shield1, mark only the surface population via extracelluar Nb, then withdraw Shield1 and follow the fate of misfolded surface FKBP\*.

We first analyzed the fate of a YFP-tagged GPI-anchored version of FKBP\* (FKBP\*-YFP-GPI) in the absence and presence of Shield1. As expected from the study of GFP-PrP\* and other GPI-anchored proteins, FKBP\*-YFP-GPI stabilized by Shield1 was primarily trafficked to the surface, while FKBP\*-YFP-GPI was primarily intracellular in the absence of Shield1. This was evident from Golgi-dependent glycan maturation only in the presence of Shield1 ([Figure 7A](#fig7){ref-type="fig"}), markedly reduced surface staining by extracellular Nb selectively in the absence of Shield1 ([Figure 7B](#fig7){ref-type="fig"}, left), and direct visualization by fluorescence microscopy (data not shown). The overall level of FKBP\*-YFP-GPI was lower at steady state in the absence of Shield1, consistent with its constitutive degradation ([Figure 7B](#fig7){ref-type="fig"}, right). Importantly, acute ER stress of FKBP\*-YFP-GPI expressing cells grown in the absence of Shield1 led to a stimulation of extracellular Nb uptake ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) and degradation ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Thus, as with GFP-PrP\*, Shield1-lacking FKBP\*-YFP-GPI is primarily retained intracellularly and degraded via a cell surface trafficking itinerary that is stimulated by acute ER stress. By contrast, Shield1-bound FKBP\*-YFP-GPI behaves like GFP-PrP and is trafficked appropriately to the cell surface where it resides at steady state.

![GPI-anchored protein acutely misfolded at the cell surface is not degraded.\
(**A**) Cells transiently transfected with FKBP\*-YFP-GPI for 48 hr were grown in the presence or absence of 2 µM Shield1, lysed, and immunoblotted using anti-GFP (which also detects YFP). (**B**) Cells stably expressing inducible FKBP\*-YFP-GPI grown with or without Shield1 were incubated on ice with 200 nM Alexa647-conjugated anti-GFP Nb and analyzed by flow cytometry for Nb fluorescence (left) or total YFP fluorescence (right). (**C**) Schematic of experimental strategy for simultaneousy monitoring the fate of inducibly misfolded FKBP\* in the cytosol and on the cell surface. The surface FKBP\* is tagged with YFP and the cytosolic FKBP\* is tagged with tagBFP. (**D**) Cells transiently transfected with FKBP\*-YFP-GPI and cytosolic FKBP\*-BFP for 48 hr were grown in the presence or absence of 2 µM Shield1. Following labeling on ice with Nb-FLAG, cells were washed and incubated for a further two hours at 37°C. During this incubation period, half of the cells previously grown in Shield1 were subjected to washout (w/o) by omitting Shield1 and further supplementing the medium with excess recombinant FKBP\* to act as a molecular 'sink' to capture any residual Shield1. After the incubation period, half of the cells were treated with extracellular trypsin to digest surface-exposed proteins before inactivating the trypsin. Following lysis, Nb-FLAG and cytosolic FKBP\*-BFP were detected by immunoblotting. (**E**) Cells transiently transfected with FKBP\*-YFP-GPI and cytosolic FKBP\*-BFP for 48 hr were grown in the presence or absence of 2 µM Shield1. In a subset of cells, Shield1 was withdrawn as in panel D for varying periods of time, after which surface-localized FKBP\*-YFP-GPI was stained with Alexa647-Nb. Levels of cytosolic FKBP\*-BFP and surface-localized FKBP\*-YFP-GPI were monitored via flow cytometry. 2.5 µg/ml Brefeldin A was included in the medium during the time course to prevent export of newly-synthesized protein.](elife-46740-fig7){#fig7}

To test the effect of acute misfolding at the cell surface ([Figure 7C](#fig7){ref-type="fig"}), cells expressing FKBP\*-YFP-GPI were cultured in the presence of Shield1, the surface population was marked with extracellular Nb, and the Shield1 was withdrawn. As expected, little or no Nb was recovered from FKBP\*-YFP-GPI cells grown without Shield1 ([Figure 7D](#fig7){ref-type="fig"}, lane 1) or from cells lacking FKBP\*-YFP-GPI ([Figure 7D](#fig7){ref-type="fig"}, lane 7). By contrast, clear Nb binding was evident in Shield1-grown FKBP\*-YFP-GPI cells ([Figure 7D](#fig7){ref-type="fig"}, lane 5). This Nb was localized at the surface as evidenced by its digestion by extracellular trypsin. Strikingly, essentially all of the initially bound Nb was still present 2 hr after Shield1 withdrawal, and these Nb molecules were still at the surface (and hence, trypsin accessible) to the same level as that observed before withdrawal ([Figure 7D](#fig7){ref-type="fig"}, lanes 3 and 4). Importantly, a cytosolic FKBP\* tagged with blue fluorescent protein (FKBP\*-BFP) expressed in the same cells was fully protected from extracellular trypsin, and mostly degraded 2 hr after Shield1 withdrawal. This cytosolic reporter provides an internal control verifying the efficacy of Shield1 withdrawal and the selectivity of trypsin digestion for only surface exposed proteins. Thus, acute destabilization of FKBP\*-GFP-GPI at the cell surface by Shield1 withdrawal does not cause its internalization from the cell surface or degradation in lysosomes.

To verify this conclusion and to exclude any possibility that pre-binding the Nb somehow prevented FKBP\*-YFP-GPI internalization, we performed the experiment in a different way. Using cells grown in Shield1 that co-express FKBP\*-BFP in the cytosol and FKBP\*-YFP-GPI at the cell surface, we withdrew Shield1 for different periods of time, stained the surface population of FKBP\*-YFP-GPI using fluorescent Nb, and analyzed the cells by flow cytometry. As expected, the FKBP\*-BFP in the cytosol was rapidly degraded after Shield1 withdrawal to the same low level observed when cells are grown in the absence of Shield1 ([Figure 7E](#fig7){ref-type="fig"}). Additionally, retaining Shield1 during the monitoring period resulted in no degradation. In the case of FKBP\*-YFP-GPI, the amount on the surface remained unchanged during the time course regardless of whether Shield1 was maintained or withdrawn. This level on the surface was markedly higher than the steady-state surface level seen when cells are cultured in the absence of Shield1.

Taken together, these results show that when FKBP\*-YFP-GPI misfolds at the time of its biogenesis at the ER, it is degraded. By contrast, when it is allowed to go to the surface as a folded protein, then misfolds, the surface population fails to be recognized as aberrant and remains there as if it were folded. This strongly indicates that not only is misfolding initially recognized in the ER, but the misfolding-dependent interactions made in the early secretory pathway need to be retained for cells to recognize protein misfolding at the cell surface. Thus, FKBP\*-YFP-GPI that misfolds in the ER and arrives at the surface is distinct from FKBP\*-YFP-GPI that misfolds at the plasma membrane: the former is associated with intracellular factors, while the latter cannot do so. This biochemical difference between these two situations appears to be a critical determinant of the misfolded protein's ultimate fate.

Discussion {#s3}
==========

We have systematically analyzed the trafficking itinerary and physical interactions made by PrP\*, a model misfolded GPI-anchored protein, during its degradation in cultured mammalian cells. Our analysis leads to a number of new insights. First, essentially all PrP\* transits the cell surface on its way to lysosomes for degradation. Second, PrP\* has a short residence time on the cell surface unlike properly folded PrP, explaining why only a tiny proportion of PrP\* is detected on the surface at steady-state. Third and most unexpectedly, PrP\* arrives at the cell surface in complex with the chaperones and cargo receptors that it engaged during its initial misfolding in the ER lumen. Finally, using a GPI-anchored protein whose misfolding could be temporally controlled in trans, we find that persistent interaction with intracellular factors is a key requirement for cellular recognition of misfolding at the cell surface. Each of these new insights has a number of important implications for our understanding of quality control in the secretory pathway and the post-ER roles of factors traditionally restricted to the early secretory pathway.

Earlier studies of both natural ([@bib8]) and artificial ([@bib37]) misfolding mutants of PrP had established that lysosomal degradation is a major pathway for their turnover. This conclusion was generalized for other GPI-anchored proteins in mammalian cells ([@bib37]) and yeast ([@bib40]). However, the route to lysosomes, while known to involve transit through the Golgi, was not clear. A major conclusion from our quantitative analysis is that the majority of PrP\* samples the cell surface prior to lysosomal degradation. Earlier qualitative antibody uptake experiments had hinted at this possibility ([@bib37]), but the extent of flux through this route was not determined. It is not known whether this conclusion applies uniformly to all GPI-anchored proteins, all types of mutants, and other organisms (e.g., yeast). However, our findings that FKBP\*, an unrelated misfolded protein, also accesses the cell surface argues for the generality of our findings.

The remarkable implication of this conclusion is that cells transiently expose misfolded proteins to the extracellular environment. This is surprising given the extensive quality control and retention pathways that eukaryotes have evolved to explicitly avoid this fate. It seems unlikely that other routes to the lysosome are not available to the cell. Indeed, inhibition of endocytosis via AP2 or dynamin perturbation, while detectably increasing the amount of PrP\* at the cell surface, does not fully trap all PrP\* at the cell surface and does not strongly impair degradation. While this finding is difficult to interpret cleanly given the pleiotropic consequences of these manipulations for other trafficking pathways and perhaps lysosome function, it does illustrate that cells have alternative degradative options for GPI-anchored proteins including ERAD ([@bib40]), and possibly direct Golgi-to-lysosome traffic ([@bib17]) or autophagy of the ER ([@bib23]). It is therefore worth considering whether the favored surface route provides an unappreciated benefit. One attractive idea is that perhaps surface exposure, either of misfolded proteins directly or of their associated chaperones (see below), is used to judge a cell's health or stress status by other cells in a metazoan organism ([@bib48]).

The misfolded GPI-anchored protein that arrives at the cell surface is complexed with chaperones and cargo receptors. Although we identified several proteins in cell surface PrP\* complexes, it is unclear whether they are all part of a single complex or instead represent heterogeneity of complexes. Regardless, their association provides a satisfying explanation for how a grossly misfolded protein can navigate the secretory pathway without risk of aggregation or inappropriate interactions. The chaperones may remain tightly bound after PrP\* leaves the ER due to the absence of co-factors that drive their recycling, thereby preventing further attempts at folding. The tight binding of chaperones, particularly the lectin CNX, nicely explains the otherwise puzzling observation that PrP\*'s glycans do not get trimmed or modified during its transit through the Golgi. This is presumably why the vast majority of PrP\* isolated from the cell surface still has immature glycans while PrP's glycans are mature.

Our attempts to directly detect endogenous chaperones and cargo receptors on the cell surface have faced substantial challenges due to the extremely low proportion of these normally ER-resident proteins on the surface combined with the limitations of available antibodies. Only \~0.5% of cellular CNX and TMED10 molecules are engaged with PrP\* on the surface ([Figure 6C](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), and possibly even less when PrP\* is not being expressed. Monitoring this tiny population requires reagents that bind with exquisitely high affinity and specificity, such as the anti-GFP nanobody that enabled us to detect surface-localised GFP-PrP\*. Unfortunately, the available antibodies against the non-cytosolic domains of endogenous ER-resident proteins do not provide sufficient signal-to-noise to reliably detect them at the cell surface or follow the fate of these minor populations. Achieving this goal will probably require development of new reagents (e.g., high affinity nanobodies) or tagging the factors in the genome in a way that does not disrupt function or trafficking.

It is unknown what ultimately happens to chaperones and cargo receptors that accompany PrP\* on its degradative route. The simplest model is that they are degraded in the lysosome and are essentially serving a terminal function. This has not been possible to test with lysosomal inhibitors because the proportion that would be stabilized is very small. Regardless, our data tracking PrP\* interactions over a 180 min time course suggests that no appreciable dissociation occurs before delivery to the late endocytic pathway. An extensive but heterogeneous literature has reported chaperones ([@bib3]; [@bib14]; [@bib31]; [@bib45]; [@bib49]) or cargo receptors ([@bib13]) in post-ER compartments including the cell surface and extracellular space. While the functional relevance of these observations has largely remained unclear, their elevated exposure has sometimes been associated with cancer cells ([@bib6]; [@bib39]; [@bib43]). Because cancer cells have a high mutation burden and are thought to express numerous misfolded proteins, elevated surface chaperones might reflect their involvement in degradation pathway(s) like the one described in this study.

As noted above, one role of retaining chaperone and cargo receptor interactions may be to shield the misfolded proteins from inappropriate interactions. Our acute surface misfolding experiments argues that a second critical function is to cue endocytosis and degradation. At present, we cannot determine which of the PrP\* surface interaction partners is critical for this endocytosis function. One model is that cells express a transmembrane 'receptor' for certain chaperones, and engagement of this receptor triggers endocytosis. Indeed, putative receptors that recognize chaperones have been described ([@bib15]), although evidence for such an interaction did not emerge from our systematic analysis of PrP\* interactions. A related model involves direct recognition of transmembrane chaperones or cargo receptors associated with PrP\*. For example, TMED family members have cytosolic tails that could be recognized for endocytosis at the plasma membrane. The currently ill-defined complex of TMEDs that associate with PrP\* and the presence of multiple family members makes testing this idea challenging, but it remains an important future goal.

It is striking that a GPI-anchored protein that misfolds at the cell surface goes unrecognized. In recent years, a growing number of studies have provided evidence for quality control at the plasma membrane. In these cases, the recognition factors are all in the cytosol and the clients are all integral membrane proteins with cytosolically exposed regions ([@bib5]; [@bib4]; [@bib33]; [@bib32]; [@bib50]). Few studies have rigorously limited the misfolding to an extracellular domain and investigated whether cells can recognize the problem. Given the constant exposure of cell surface proteins to the changing and often harsh extracellular environment, one might have predicted the existence of a mechanism for detection of misfolded extracellular domains. While our data do not exclude such a system, its mode of recognition must differ from that used in the cytosol given the different behavior of Shield1-lacking FKBP\* in the two compartments. Given that PrP\* is associated with intracellular factors at the surface, we posit that GPI-anchored proteins as a class rely on this mechanism for their recognition at the plasma membrane.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\         Designation                 Source or reference   Identifiers                                                          Additional information
  (species) or\                                                                                                                                
  resource                                                                                                                                     
  --------------------- --------------------------- --------------------- -------------------------------------------------------------------- ---------------------------------
  Cell line\            HEK293T                     ATCC CRL-3216         RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)           
  (*Homo sapiens*)                                                                                                                             

  Cell line\            HEK293 TRex Flp-in          Invitrogen            RRID:[CVCL_U427](https://scicrunch.org/resolver/CVCL_U427)           
  (*H. sapiens*)                                                                                                                               

  Cell line\            HEK293 TRex GFP-PrP\*       This paper                                                                                 GFP-PrP\* (see below)\
  (*H. sapiens*)                                                                                                                               integrated into FRT\
                                                                                                                                               site of HEK293 Trex\
                                                                                                                                               Flp-in cell line

  Cell line\            HEK293 TRex GFP-PrP         This paper                                                                                 GFP-PrP (see below)\
  (*H. sapiens*)                                                                                                                               integrated into FRT\
                                                                                                                                               site of HEK293 Trex\
                                                                                                                                               Flp-in cell line

  Cell line\            HEK293 TRex\                This paper                                                                                 Disruption of TMED10\
  (*H. sapiens*)        GFP-PrP\* TMED10 KO                                                                                                    by CRISPR/Cas9 in\
                                                                                                                                               GFP-PrP\* cell line

  Cell line\            HEK293 TRex\                This paper                                                                                 Disruption of TMED10\
  (*H. sapiens*)        GFP-PrP TMED10 KO                                                                                                      by CRISPR/Cas9 in\
                                                                                                                                               GFP-PrP cell line

  Cell line\            HEK293 TRex\                This paper                                                                                 FKBP\*-YFP-GPI\
  (*H. sapiens*)        FKBP\*-YFP-GPI                                                                                                         (see below) integrated\
                                                                                                                                               into FRT site of HEK293\
                                                                                                                                               Trex Flp-in cell line

  Antibody              rabbit polyclonal\          [@bib41]                                                                                   (1:5000)
                        anti-GFP                                                                                                               

  Antibody              rabbit polyclonal\          [@bib41]                                                                                   (1:3000)
                        anti-RFP                                                                                                               

  Antibody              mouse monoclonal\           Sigma                 Cat \#A8592,\                                                        (1:10000)
                        anti-FLAG (M2)-HRP\                               RRID:[AB_439702](https://scicrunch.org/resolver/AB_439702)           
                        conjugated                                                                                                             

  Antibody              rabbit polyclonal\          [@bib37]                                                                                   (1:1000)
                        anti-TMED10 C-terminus                                                                                                 

  Antibody              rabbit polyclonal\          [@bib28]                                                                                   (1:6000)
                        anti-TMED2                                                                                                             

  Antibody              rabbit polyclonal\          [@bib28]                                                                                   (1:5000)
                        anti-TMED10 lumenal\                                                                                                   
                        domain                                                                                                                 

  Antibody              rabbit polyclonal\          [@bib28]                                                                                   (1:5000)
                        anti-TMED7                                                                                                             

  Antibody              rabbit polyclonal\          [@bib28]                                                                                   (1:3000)
                        anti-TMED9                                                                                                             

  Antibody              rabbit polyclonal\          Enzo                  Cat \#ADI-SPA-865,\                                                  (1:2000 -- 1:5000)
                        anti-CNX N-terminus                               RRID:[AB_10618434](https://scicrunch.org/resolver/AB_10618434)       

  Antibody              rabbit polyclonal\          Enzo                  Cat \#ADI-SPA-860,\                                                  (1:2000)
                        anti-CNX C-terminus                               RRID:[AB_10616095](https://scicrunch.org/resolver/AB_10616095)       

  Antibody              rabbit polyclonal anti\     evrogen               Cat \#AB233,\                                                        (1:2000)
                        tagRFP (also recognizes\                          RRID:[AB_2571743](https://scicrunch.org/resolver/AB_2571743)         
                        tagBFP)                                                                                                                

  Antibody              mouse monoclonal\           BD Biosciences        Cat \#610502,\                                                       (1:3000)
                        anti-alpha adaptin (AP2)                          RRID:[AB_397868](https://scicrunch.org/resolver/AB_397868)           

  Antibody              mouse monoclonal\           Invitrogen            Cat \#136800,\                                                       (1:500)
                        anti-Transferrin receptor                         RRID:[AB_2533029](https://scicrunch.org/resolver/AB_2533029)         

  Recombinant DNA\      pRSET-Nanobody-3x\          This paper                                                                                 Nanobody sequence\
  reagent               FLAG-His                                                                                                               from Addgene plasmid\
                                                                                                                                               \#49172

  Recombinant DNA\      pX330-TMED10\               This paper                                                                                 sgRNA targeting\
  reagent               sgRNA2                                                                                                                 TMED10

  Recombinant DNA\      pX330-TMED10\               This paper                                                                                 sgRNA targeting\
  reagent               sgRNA3                                                                                                                 TMED10

  Recombinant DNA\      pcDNA3-HA-TMED10            This paper                                                                                 Human TMED10 with\
  reagent                                                                                                                                      HA tag following signal\
                                                                                                                                               sequence

  Recombinant DNA\      pcDNA3-HA-TMED10\           This paper                                                                                 HA-tagged human TMED10\
  reagent               si2R                                                                                                                   as above with silent mutations\
                                                                                                                                               to confer resistance to\
                                                                                                                                               Stealth RNAi TMED10HSS\
                                                                                                                                               145904

  Recombinant DNA\      pcDNA3-HA-RFP-TMED10        This paper                                                                                 Human TMED10 with HA\
  reagent                                                                                                                                      tag and RFP following\
                                                                                                                                               signal sequence

  Recombinant DNA\      pcDNA3-HA-TMED10 ΔCC        This paper                                                                                 Human HA-TMED10\
  reagent                                                                                                                                      lacking coiled-coil domain\
                                                                                                                                               (amino acids 130--183)

  Recombinant DNA\      pcDNA3-HA-RFP-TMED10\       This paper                                                                                 Human HA-RFP-TMED10\
  reagent               ΔGOLD                                                                                                                  with GOLD domain\
                                                                                                                                               deleted (residues 41--129\
                                                                                                                                               of original protein)

  Recombinant DNA\      pcDNA3-HA-RFP-TMED10\       This paper                                                                                 Human HA-RFP-TMED10\
  reagent               ΔCC                                                                                                                    lacking coiled-coil domain\
                                                                                                                                               (amino acids 130--183)

  Recombinant DNA\      FKBP12-YFP-GPI              [@bib38]                                                                                   
  reagent                                                                                                                                      

  Recombinant DNA\      FKBP\*-YFP-GPI              This paper                                                                                 F36V and L106P\
  reagent                                                                                                                                      mutations introduced\
                                                                                                                                               into FKBP12-YFP-GPI

  Recombinant DNA\      pcDNA5-FRT/TO-FKBP\         This paper                                                                                 FKBP\*-YFP-GPI subcloned\
  reagent               \*-YFP-GPI                                                                                                             into pcDNA5-FRT/TO for\
                                                                                                                                               stable inducible expression

  Recombinant DNA\      FKBP\*-BFP                  This paper                                                                                 FKBP\* followed by BFP\
  reagent                                                                                                                                      for cytosolic expression

  Recombinant DNA\      pET15b-HisFKBP\*12 F36V     Addgene               Cat \#73180,\                                                        
  reagent                                                                 RRID:[Addgene_73180](https://scicrunch.org/resolver/Addgene_73180)   

  Recombinant DNA\      FusionRed-Dynamin\          [@bib2]                                                                                    Dominant-negative\
  reagent               S45N                                                                                                                   dynamin mutant

  Recombinant DNA\      pcDNA3-3xmyc-TMED2          This paper                                                                                 Human TMED2 with\
  reagent                                                                                                                                      3xmyc tag following\
                                                                                                                                               signal sequence.

  Recombinant DNA\      pRSET-Nanobody-\            This paper                                                                                 Nanobody-APEX2-FLAG\
  reagent               APEX2-3xFLAG-His                                                                                                       for bacterial expression.\
                                                                                                                                               APEX2 sequence from\
                                                                                                                                               Addgene plasmid \#49386

  Recombinant DNA\      mGFP1-N1                    Clontech                                                                                   
  reagent                                                                                                                                      

  Recombinant DNA\      pcDNA5-FRT/TO-\             This paper                                                                                 C179A mutant of hamster\
  reagent               EGFP-PrP\*                                                                                                             PrP with bovine prolactin\
                                                                                                                                               signal sequence; EGFP @\
                                                                                                                                               unique Bsu36I site\
                                                                                                                                               downstream of signal\
                                                                                                                                               sequence.

  Recombinant DNA\      pcDNA5-FRT/TO-\             This paper                                                                                 Wild-type human PrP,\
  reagent               EGFP-PrP                                                                                                               with EGFP @ unique\
                                                                                                                                               Bsu36I site downstream\
                                                                                                                                               of signal sequence.

  Sequence-based\       CRISPR: TMED10\             IDT                                                                                        TAACGGAAAAGGGCCGCGCC
  reagent               sgRNA2                                                                                                                 

  Sequence-based\       CRISPR: TMED10\             IDT                                                                                        GCAGCAACGCTAACGGAAAA
  reagent               sgRNA3                                                                                                                 

  Sequence-based\       siRNA: nontargeting\        Dharmacon             D-001810--10                                                         
  reagent               control                                                                                                                

  Sequence-based\       siRNA: AP2\                 Dharmacon                                                                                  gift of B. Nichols lab\
  reagent               (alpha-adaptin)                                                                                                        (MRC-LMB)

  Sequence-based\       siRNA: nontargeting\        Thermo Fisher         4390843                                                              Silencer Select
  reagent               control                                                                                                                

  Sequence-based\       siRNA: TMED1 (a)            Thermo Fisher         s21699                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED1 (b)            Thermo Fisher         s21700                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED2 (a)            Thermo Fisher         s21570                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED2 (b)            Thermo Fisher         s21571                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED3 (a)            Thermo Fisher         s23799                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED3 (b)            Thermo Fisher         s23800                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED4 (a)            Thermo Fisher         s48156                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED4 (b)            Thermo Fisher         s48157                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED5 (a)            Thermo Fisher         s27202                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED5 (b)            Thermo Fisher         s27203                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED6 (a)            Thermo Fisher         s44861                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED6 (b)            Thermo Fisher         s44862                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED7 (a)            Thermo Fisher         s27238                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED7 (b)            Thermo Fisher         s27239                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED9 (a)            Thermo Fisher         s29353                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED9 (b)            Thermo Fisher         s29354                                                               Silencer Select
  reagent                                                                                                                                      

  Sequence-based\       siRNA: TMED10               Thermo Fisher         HSS145904                                                            Stealth siRNA
  reagent                                                                                                                                      

  Sequence-based\       siRNA: negative control     Thermo Fisher         46--2001                                                             Stealth siRNA
  reagent                                                                                                                                      

  Peptide,\             Nanobody-FLAG-His           This paper                                                                                 purified from *E. coli*\
  recombinant protein                                                                                                                          (BL21) pLysS cells\
                                                                                                                                               using immobilized metal\
                                                                                                                                               affinity chromatography

  Peptide,\             Nanobody-FLAG-APEX2         This paper                                                                                 purified from *E. coli* (BL21)\
  recombinant protein                                                                                                                          pLysS cells using\
                                                                                                                                               immobilized metal\
                                                                                                                                               affinity chromatography

  Peptide,\             FKBP12 (F36V)               [@bib20]                                                                                   purified from *E. coli* (BL21)\
  recombinant protein                                                                                                                          pLysS cells using\
                                                                                                                                               immobilized metal\
                                                                                                                                               affinity chromatography

  Chemical\             Thapsigargin                Sigma                 Cat \#T9033                                                          
  compound, drug                                                                                                                               

  Chemical\             Bafilomycin A1              Sigma                 Cat \#B1793                                                          
  compound, drug                                                                                                                               

  Chemical\             Brefeldin A                 Invitrogen            Cat \#B7450                                                          
  compound, drug                                                                                                                               

  Chemical\             Shield1                     Clontech/Takara       Cat \#632189                                                         
  compound, drug                                                                                                                               

  Chemical\             Cycloheximide               Sigma                 Cat \#C4859                                                          
  compound, drug                                                                                                                               

  Chemical\             Alexa Fluor546\             Invitrogen            Cat \#A20002                                                         
  compound, drug        NHS Ester                                                                                                              

  Chemical\             Alexa Fluor647\             Invitrogen            Cat \#A37566                                                         
  compound, drug        NHS Ester                                                                                                              

  Chemical\             TMT labeling\               Thermo Fisher         Cat \#90110                                                          
  compound, drug        reagents                                                                                                               

  Chemical\             biotin-phenol               Iris Biotech          Cat \#LS-3500                                                        
  compound, drug                                                                                                                               

  Other                 GFP-trap                    Chromotek             Cat \#gta-20                                                         

  Other                 anti-FLAG M2\               Sigma                 Cat \#A2220                                                          
                        affinity resin                                                                                                         

  Other                 Streptavidin-HRP            Thermo Fisher         Cat \#43--4323                                                       

  Other                 Streptavidin T1\            Invitrogen            Cat \#65601                                                          
                        Dynabeads                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s4-1}
------------

Flp-in T-Rex HEK293 cells (Invitrogen) and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). In cases where the cells contained a stably expressed doxycycline-inducible protein, tetracycline-free FBS was used as well as 10 μg/ml blasticidin and 100 μg/ml hygromycin. Cells inducibly expressing GFP-PrP, GFP-PrP\*, and FKBP\*-YFP-GPI were made by integrating the respective expression cassettes into the FRT site of Flp-in T-Rex HEK293 cells by Flp recombination (Invitrogen). 10 ng/ml doxycycline was used for induction of the integrated gene at the FRT site. All cell lines were checked for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza) and found to be negative. Cell line identities were verified by a combination of an integrated FRT site and doxycycline inducibility (distinctive to Flp-in T-Rex cells), by antibiotic resistance markers, by homogeneous fluorescent reporter expression, and by immunoblotting for the product of knockout alleles. Further genetic analysis was not performed. Transient transfections were performed using TransIT-293 (Mirus Bio), according to manufacturer's instructions. For flow cytometry experiments in which expression constructs did not contain a fluorescent protein, RFP was co-transfected as a transfection marker so that only transfected cells could be analyzed. siRNA silencing was performed with Lipofectamine RNAiMAX (Life Technologies) as directed by the manufacturer. AP2 siRNA was obtained from Dharmacon and used at 20 nM. Silencing was allowed to proceed for 96 hr after transfection prior to analysis. Silencer Select siRNAs against TMED family proteins were obtained from ThermoFisher, and used at 10 nM. Silencing was allowed to proceed for 72 hr after transfection prior to analysis. Gene disruption of TMED10 by CRISPR was performed as described ([@bib35]) with the following guide RNA sequences: TAACGGAAAAGGGCCGCGCC and GCAGCAACGCTAACGGAAAA. Clones were verified by immunoblotting to be disrupted for TMED10, and knockout cell lines with either guide behaved the same way.

Constructs {#s4-2}
----------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Plasmid name                   Purpose                     Brief description                Backbone vector                                    Promoter
  ------------------------------ --------------------------- -------------------------------- -------------------------------------------------- ------------
  pRSET-Nanobody-3xFLAG-His      bacterial expression        3xFLAG-tagged anti-GFP\          pRSET                                              T7
                                                             nanobody                                                                            

  pX330-TMED10 sgRNA2            mammalian cell expression   sgRNA targeting\                 pX330 (ΔCas9)                                      U6
                                                             TMED10\                                                                             
                                                             (TAACGGAAAAGGGCCGCGCC)                                                              

  pX330-TMED10 sgRNA3            mammalian cell expression   sgRNA targeting\                 pX330 (ΔCas9)                                      U6
                                                             TMED10\                                                                             
                                                             (GCAGCAACGCTAACGGAAAA)                                                              

  pcDNA3-HA-TMED10               mammalian cell expression   Human TMED10 with HA tag\        pcDNA3.1 (+) zeo                                   CMV
                                                             following signal sequence                                                           

  pcDNA3-HA-TMED10 si2R          mammalian cell expression   HA-tagged human TMED10\          pcDNA3.1 (+) zeo                                   CMV
                                                             as above with silent\                                                               
                                                             mutations to confer\                                                                
                                                             resistance to Stealth\                                                              
                                                             RNAi TMED10HSS145904                                                                

  pcDNA3-HA-RFP-TMED10           mammalian cell expression   Human TMED10 with HA\            pcDNA3.1 (+) zeo                                   CMV
                                                             tag and RFP following\                                                              
                                                             signal sequence                                                                     

  pcDNA3-HA-TMED10 ΔCC           mammalian cell expression   Human TMED10 lacking\            pcDNA3.1 (+) zeo                                   CMV
                                                             coiled-coil domain (amino\                                                          
                                                             acids 130--183); HA-tagged                                                          

  pcDNA3-HA-RFP-TMED10 ΔGOLD     mammalian cell expression   GOLD domain deleted\             pcDNA3.1 (+) zeo                                   CMV
                                                             (residues 41--129 of original\                                                      
                                                             protein); HA- and RFP-tagged                                                        

  pcDNA3-HA-RFP-TMED10 ΔCC       mammalian cell expression   Human TMED10 lacking\            pcDNA3.1 (+) zeo                                   CMV
                                                             coiled-coil domain\                                                                 
                                                             (amino acids 130--183);\                                                            
                                                             HA- and RFP-tagged                                                                  

  FKBP\*12(F36V/L106P)-YFP-GPI   mammalian cell expression   FKBP\*12 containing\             Derived from FKBP12-YFP-GPI\                       
                                                             destabilizing mutations,\        ([@bib38]) provided by\                            
                                                             followed by YFP and GPI-\        J. Lippincott-Schwartz                             
                                                             anchor signal. For transient\                                                       
                                                             expression.                                                                         

  FKBP\*12(F36V/L106P)-BFP       mammalian cell expression   FKBP\*12 containing\             pcDNA3.1 (+) zeo                                   CMV
                                                             destabilizing mutations,\                                                           
                                                             followed by BFP                                                                     

  pcDNA5-FRT/TO-YFP-\            mammalian cell expression   FKBP\*12 containing\             pcDNA5/FRT/TO                                      CMV Tet-on
  FKBP\*12(F36V/L106P)-GPI                                   destabilizing mutations,\                                                           
                                                             followed by YFP and GPI-\                                                           
                                                             anchor signal. For stable-\                                                         
                                                             inducible expression.                                                               

  pET15b-HisFKBP\*12 F36V        bacterial expression        Recombinant FKBP\*12\            Created by T. Wandless (Addgene Plasmid \#73180)   
                                                             to bind excess Shield1\                                                             
                                                             during washout.                                                                     

  FusionRed-Dynamin S45N         mammalian cell expression   Dominant-negative\               Gift from H. McMahon\'s lab (MRC-LMB, Cambridge)   
                                                             dynamin mutant                                                                      

  pcDNA3-3xmyc-TMED2             mammalian cell expression   Human TMED2 with 3xmyc\          pcDNA3.1 (+) zeo                                   CMV
                                                             tag following\                                                                      
                                                             signal sequence.                                                                    

  nanobody APEX2                 bacterial expression        nanobody-APEX2-FLAG\             pRSET                                              T7
                                                             for bacterial expression                                                            

  mGFP1-N1                       mammalian cell expression   cytosolic GFP                    pmGFP                                              

  pcDNA5-FRT/TO-EGFP-PrP\*       mammalian cell expression   C179A mutant of hamster\         pcDNA5/FRT/TO                                      CMV Tet-on
                                                             PrP with bovine prolactin\                                                          
                                                             signal sequence; EGFP\                                                              
                                                             @ unique Bsu36I site\                                                               
                                                             downstream of signal\                                                               
                                                             sequence.                                                                           

  pcDNA5-FRT/TO-EGFP-PrP         mammalian cell expression   Wild-type human PrP,\            pcDNA5/FRT/TO                                      CMV Tet-on
                                                             with EGFP @ unique Bsu36I\                                                          
                                                             site downstream of signal\                                                          
                                                             sequence.                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Antibodies and recombinant proteins {#s4-3}
-----------------------------------

The following antibodies were used in this study have either been described previously or obtained from sources: custom rabbit antisera raised against recombinant GFP and RFP ([@bib41]); anti-FLAG (M2)-HRP conjugated (Sigma); rabbit anti-TMED10 raised against a C terminal peptide ([@bib37]); rabbit anti-TMED2, anti-TMED7, anti-TMED9, and anti-TMED10 lumenal domain (gift of Felix Weiland); anti-CNX N-terminus (Enzo ADI-SPA-865); rabbit anti-CNX C terminus (Enzo ADI-SPA-860); rabbit anti tagBFP (evrogen anti-tRFP AB233); mouse anti-AP2 (anti-alpha adaptin, BD Biosciences 610502); mouse anti-Transferrin receptor (Invitrogen 136800); mouse anti-BiP (BD Biosciences 610979). In addition, anti-GFP nanobody was recombinantly expressed in *E. coli*, purified, and labeled with fluorophores as described next.

His-tagged Nanobody-FLAG, Nanobody-FLAG-APEX2, and FKBP\*12(F36V) were purified from *E. coli* (BL21) pLysS cells using immobilized metal affinity chromatography. In brief, cells were transformed with the expression plasmids encoding the desired proteins and grown at 37°C in LB under the appropriate antibiotic selection. Expression was induced with 0.1 mM IPTG when bacteria reached an A~600~ of 0.6. Induction proceeded at 16--18°C overnight. Cells were harvested by centrifugation, resuspended in 30 ml ice cold lysis buffer \[1X PBS, 300 mM NaCl, 10 mM imidazole, DNase, 1 mM β-mercaptoethanol, 1 mM PMSF, 1 mM Benzamidine, 1X protease inhibitor cocktail (Roche)\] per L culture, and lysed by sonication. The lysates were clarified by centrifugation and passed by gravity flow over columns of chelating sepharose (GE Healthcare Life Sciences) charged with Co^2+^. Columns were successively washed with 10 column volumes each of lysis buffer containing 10, 15, and 20 mM imidazole. Proteins were eluted with 200 mM imidazole in 1xPBS and 150 mM NaCl. Peak elutions as judged by A~280~ readings were pooled. In most cases, the proteins were desalted into PBS using a PD-10 column (GE Healthcare). All proteins were supplemented with 10% glycerol prior to storage. To make fluorescently tagged nanobody, 190 nmol of purified nanobody was mixed with 1 mg Alexa Fluor NHS Ester in 50 mM NaHCO~3~ for 1 hr at room temperature, and subsequently separated from free dye by desalting through a PD-10 column equilibrated in PBS.

Flow cytometry {#s4-4}
--------------

Cells were resuspended by gentle pipetting in PBS. Unless otherwise indicated, cell surface labeling was performed on ice for 30 min with 200 nM Alexa546- or Alexa647-conjugated anti-GFP Nb in PBS containing 10% FBS. In experiments measuring nanobody internalization, 10 nM Nb was added to the extracellular medium and cells were incubated for the indicated times at 37°C. Total GFP or YFP fluorescence was measured in cells that were not incubated with fluorescent Nb in order to avoid mild fluorescence quenching effects on GFP that were observed upon Nb binding. Cells in both surface labeling and internalization experiments were subsequently washed in PBS and resuspended in 10% FBS with 1 ug/ml DAPI as a viability marker (except when a BFP-conjugated protein was present), and filtered through a 70 μm mesh to remove any clumped cells. Cells were subsequently analyzed on a Beckton Dickinson LSRII or LSRFortessa flow cytometer, and data was analyzed using FlowJo software. A minimum of 10,000 transfected cells were analyzed in each condition. Each experiment is internally controlled and the control cells that are shown in each graph were grown, harvested, and analyzed in parallel with the experimental sample. The numerical values of fluorescence intensity cannot be directly compared across experiments because the absolute number assigned to nanobody fluorescence is dependent on the model of flow cytometer, the settings, and calibration. In Figure 4C, 10^6^ TMED10-transfected cells were selected on the basis of moderate RFP fluorescence using a Sony Biotechnology Synergy High Speed Cell Sorter.

Fluorescence microscopy {#s4-5}
-----------------------

For fixed cell imaging, cells were plated on 13 mm round coverslips (VWR), fixed in 4% formaldehyde, and imaged using a Nikon TE2000 inverted fluorescence microscope using a 100x objective. For live cell imaging, cells were plated on μ-dishes (ibidi) and imaged using an Andor Revolution Spinning Disk inverted microscope, 60x objective. When live cells were imaged over a time course ([Figure 1E](#fig1){ref-type="fig"}), dishes were coated with 10 μg/ml fibronectin for 1 hr at 37°C and washed three times with PBS prior to seeding cells, in order to enhance cell adherence. When necessary, image brightness was adjusted by equivalent amounts in all conditions using Fiji software or Adobe Photoshop.

Sucrose gradient fractionation {#s4-6}
------------------------------

Analytical scale 0.2 mL gradients were prepared in 7 × 20 mm centrifuge tubes (Beckman 343775) by successively layering 40 μL of 25%, 20%, 15%, 10%, and 5% sucrose (w/v) in 50 mM HEPES pH 7.4, 150 mM NaCl, 1% CHAPS. Gradients were then allowed to stand for 35--60 min at 4°C. The samples in lysis buffer (50 mM HEPES, 150 mM NaCl, 1% CHAPS) were loaded on top of the gradients and centrifuged in a TLS- 55 rotor at 55,000 rpm for 2 hr 25 min at 4°C with slow acceleration and deceleration. Eleven 20 μL fractions were successively collected from the top and used directly for western blot analysis.

Immunoprecipitation {#s4-7}
-------------------

In order to isolate the surface-localized population of GFP-PrP and GFP-PrP\*, cells were labeled on ice for 1 hr with 200 nM 3xFLAG-tagged anti-GFP Nb, then washed to remove all free Nb. The cells were then sedimented by centrifugation prior to lysis. For both surface and total immunoprecipitation experiments, cells were lysed in 50 mM HEPES, 150 mM NaCl, 1% CHAPS, and EDTA-free protease inhibitor cocktail (Roche). The insoluble material was removed by centrifugation at maximum speed in a microcentrifuge for 10 min at 4°C. The soluble fraction was incubated with anti-FLAG M2 affinity resin (Sigma) for surface IPs, and anti-GFP nanobody conjugated to sepharose beads (Chromotek and homemade) for GFP IPs at 4°C for 1--4 hr. Beads were washed three times in lysis buffer and eluted with 0.1 mg/ml 3x-FLAG peptide or 2x sample buffer (100 mM Tris pH 6.8, 2% SDS, 20% glycerol, 200 mM DTT) prior to further analysis.

Mass spectrometry {#s4-8}
-----------------

For protein identification in immunoprecipitation experiments, eluates were separated by SDS-PAGE and excised gel bands were washed, reduced with DTT, alkylated with iodoacetamide (IAA) and digested with trypsin in ammonium bicarbonate overnight at 37°C. Extracted peptide mixtures were analyzed by LC/MS/MS in an Orbitrap Velos mass spectrometer (Thermo Fisher Scientific). Quantitative mass spectrometry was performed by on-bead trypsin digestion of samples, followed by tandem mass tag (TMT) labelling. In brief, protein samples on beads were reduced with 10 mM DTT at 56°C for 30 min and alkylated with 15 mM IAA for 30 min in the dark at 22°C. The alkylation reaction was quenched by the addition of DTT and samples were digested with trypsin (Promega) overnight at 37°C. Each supernatant was transferred to a fresh Eppendorf tube, and the beads were extracted once with 50% acetonitrile/0.1% TFA and combined with the corresponding supernatant. The peptide mixtures were then partially dried in a Speed Vac and desalted using C18 (3M Empore) stage tips containing Poros R3 resin (Applied Biosystems). Bound peptides were eluted sequentially with 30%, 50% and 80% acetonitrile in 0.1%TFA and lyophilized. Dried peptide mixtures from each condition were re-suspended in 40 ul of 5% acetonitrile, 200 mM triethyl ammonium bicarbonate. For TMT labelling, 0.8 mg of TMT reagents (Thermo Fisher Scientific) were reconstituted in 41 ul anhydrous acetonitrile. 10--15 ul of TMT was added to each peptide mixture and incubated for 1 hr at room temperature. The labeling reactions were terminated by incubation with 4 ul 5% hydroxylamine for 15 min, and labeled samples were subsequently pooled. A Speed Vac was used to remove acetonitrile, and samples were desalted as above. In the experiment in which cells were subjected to ER stress, samples were additionally fractionated with C18 stage tips using 10 mM ammonium bicarbonate and acetonitrile gradients and acidified. Liquid chromatography was performed on a fully automated Ultimate 3000 RSLC nano System (Thermo Scientific) fitted with a 100 µm x 2 cm PepMap100 C18 nano trap column and a 75 μm × 25 cm reverse phase C18 nano column (Aclaim PepMap, Thermo Scientific). Samples were separated using a binary gradient consisting of buffer A (2% acetonitrile, 0.1% formic acid) and buffer B (80% acetonitrile, 0.1% formic acid). Peptides were eluted at 300 nL/min with an acetonitrile gradient. The HPLC system was coupled to a Q Exactive Plus hybrid quardrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a nanospray ion source. The acquired raw MS/MS files were processed using Proteome Discoverer (version 2.1, Thermo Scientific) or MaxQuant ([@bib18]) with the integrated Andromeda search engine.

Proximity biotinylation {#s4-9}
-----------------------

Proximity labeling was performed as described ([@bib27]). In brief, cells were labeled on ice for 30 min with anti-GFP nanobody conjugated to APEX2 at 200 nM (saturating) or 0.5 nM (to achieve sub-saturating labeling of GFP-PrP). Excess nanobody was removed by washing in PBS, and cells were resuspended in 500 μm biotin-phenol (Iris Biotech LS-3500) in PBS at room temperature. Hydrogen peroxide (Sigma) was added to a final concentration of 1 mM for 1 min before quenching with 10 mM sodium ascorbate (Sigma), 5 mM Trolox (Acros), and 10 mM sodium azide (VWR). Cells were washed three times in PBS containing the quenching reagents, pelleted, and lysed as above. Biotinylated proteins were detected by western blotting using HRP-conjugated streptavidin (ThermoFisher 43--4323). For isolation of biotinylated proteins, cells were lysed in 50 mM HEPES, 150 mM NaCl, 2 mM MgAc, and 1% CHAPS. Lysates were desalted using a Sephadex G-25 column to remove excess biotin-phenol, and incubated with Streptavidin T1 Dynabeads (Invitrogen) overnight at 4°C. Beads were subjected to a series of stringent washes in lysis buffer; 1% SDS in 10 mM HEPES; 1 M KCl in 10 mM HEPES with 0.5% CHAPS; and 2 M urea in 10 mM Tris with 0.5% CHAPS. Proteins were eluted in sample buffer containing 2 mM biotin.
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Drugs were used at the following concentrations: thapsigargin (Sigma) at 100 nM, Bafilomycin A1 (Sigma) at 250 nM, Brefeldin A (Invitrogen) at either 2.5 μg/ml or 1 μM as indicated, Shield1 (Clontech/Takara) at 2 uM, and Cycloheximide (Sigma) at 100 μg/ml.

Funding Information
===================

This paper was supported by the following grant:

-   http://dx.doi.org/10.13039/501100000265Medical Research Council MC_UP_A022_1007 to Ramanujan S Hegde.

We are grateful for Sew-Yeu Peak-Chew and Mark Skehel for excellent mass spectrometry analysis, Maria Daly for flow cytometry support, Eisuke Itakura for early experiments initially characterizing the stable cell lines, Michael Maurer for help with TMED10 mutant analysis, Kota Yanagitani for FKBP\* constructs, Patrick Chitwood for help with microscopy, Szymon Juszkiewicz and Patrick Chitwood for comments on this manuscript, Aarthi Ashok, Sean Munro, and Liz Miller for useful discussions, and Hegde Lab members for support. This work was supported by the UK Medical Research Council (MC_UP_A022_1007 to RSH) an MRC Career Development Fellowship (to EZ).

Additional information {#s5}
======================

Reviewing editor, *eLife*.

No competing interests declared.

Conceptualization, Investigation, Methodology, Writing---original draft, Writing---review and editing.

Conceptualization, Supervision, Funding acquisition, Writing---original draft, Writing---review and editing.

Additional files {#s6}
================

10.7554/eLife.46740.019

Data availability {#s7}
=================

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data has been provided for Figure 5E.

10.7554/eLife.46740.020

Decision letter

Schuldiner

Maya

Reviewing Editor

Weizmann Institute

Israel

Goder

Veit

Reviewer

University of Seville

Spain

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Misfolded GPI-anchored proteins are escorted through the secretory pathway by ER-derived factors\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and David Ron as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Veit Goder (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Please find below the summary of the paper and the main points that we would like you to address before resubmission.

The presented work addresses the cellular mechanisms that operate in post-ER protein quality control. Using mammalian cell culture as a model system, the authors investigate how misfolded GPI-anchored proteins (GPI-APs) are routed to the lysosome for degradation. Surprisingly, they show that the entire population of misfolded GPI-APs is first routed to the cell surface. This is followed by rapid internalization via endocytosis and routing to the lysosome. The physiological relevance for this \"extended\" traffic from the ER to the lysosome via the cell surface remains unclear, but the authors provide some interesting theories in the Discussion section.

Most relevant, however, are their findings that several ER chaperones and trafficking receptors remain bound to misfolded GPI-APs all along their way to the cell surface. This is a new concept and provides insight into novel cellular mechanisms. The interactions with ER chaperones and receptors are specific for misfolded GPI-APs; a correctly folded species is not associated with chaperones and only drastically less with trafficking receptors after ER exit. Moreover, the presence of chaperones and trafficking factors in complex with misfolded GPI-APs at the cell surface is crucial for their endocytosis and subsequent degradation. Thus, some \"post-ER quality control mechanisms\" for a subclass of proteins of the secretory pathways involve in fact ER chaperones.

The work is outstanding, the experimental approaches are original and the data are solid. This work will be highly suitable for *eLife* with only minor changes or additions requested below:

Experimental additions:

1\) In Figure 1D the authors show complete degradation by 3 hours of PrP\*-GFP in the presence of CHX but in Figure 1E the time lapse only continues until 2 hours (120 minutes) with no CHX. It would be important to see the microscopy that correlates with the flow cytometry of Figure 1D (time points until 3 hours +CHX) to ensure that there is no change in trafficking pattern with CHX or at longer times.

2\) Figure 6D exploits the high on rates of the RFP nanobodies for RFP, such that RFP-TMED10 molecules at the cell surface pick up the nanobody, internalise it and the fluorescent label of the nanobody accumulates in the cell and generates a FACS signal. Could the authors expand on the client dependence of this process: Was it enhanced by co-expression of PrP\*? By exposure of the cells to thapsigargin? Was it inhibited by brefeldin A? Have the authors tried to detect PrP\*/thapsigargin dependent exposure of BiP or CNX on the cell surface by FACS?

The claim that PrP\* is accompanied by ER resident proteins to the cell surface is one of this paper\'s most important. Right now the strongest support of this is the RFP-TMED10 expression on the cell surface however in this experiment TMED10 is overexpressed and this can lead to abnormal trafficking of this protein. Hence, any evidence to support further the notion of ER chaperones traveling with clients all the way to the cell surface on their way to degradation would greatly strengthen the manuscript.

Textual changes:

1\) In the Introduction when PrP is first introduced the authors may want to already mention that PrP is a model GPI anchor protein.

2\) In the first Results section the authors write GFP-wtPrP -- this \"wt\" denotation is not required nor is it used elsewhere.

3\) In Figure 3---figure supplement 1E -- it would be helpful to the readers to label on the images that they are KO of TMED10.

4\) Figure 5B -- it would be helpful to readers if it is labeled on the panel itself that KO refers to KO of TMED10

5\) In Figure 4D the authors arrive to some conclusions about requirements of various TMED family members for PrP\* trafficking based on siRNA knockdown experiments. However, since the non-requirement of some TMEDs is discussed based on the absence of phenotype, the authors should show the effectiveness of knockdown (or wait with the conclusion until showing the supporting interactome data in the next figure).

6\) Figure 4---figure supplement 1A and Figure 6 for all sucrose gradients, a MW standard would be helpful.

7\) Figure 5F -- The extended interaction of TMED10 also with GFP-wtPrP: could that be due to the GFP moiety on wtPrP, (slow folding?), can this be checked with wtPrP without a tag?

8\) In Figure 2E to G, the surface levels of GFP-PrP\* were analyzed by AP2 knockdown, expression of Dynamin or brefeldin A treatment. However, since the Nb fluorescence levels are very different between Figure 2E, F and G, it is difficult to judge the results. For example, the fluorescence levels of AP2-KD in Figure 2E is similar to those of control in Figure 2F and G. Please double check this and provide more representative images if possible or just double check the reproducibility.

9\) In Figure 6C, the authors showed that surface PrP\* associates with calnexin and TMED10. As the control, they used PrP and loaded only 5% of the IP fraction. Please elaborate on whether, even if the authors load 100% wild-type PrP samples, the calnexin and TMED10 are not detected in the IP fraction?

10\) Similarly, in Figure 6F, did the authors load same amounts of samples in the strep PD fraction? If so, pull downed Nb-APEX was the same level between PrP and PrP\* samples, even if the surface expressions of PrP and PrP\* were quite different. Is it correct?

11\) In Figure 6D, the authors analyzed the internalization of anti-RFP nanobody in RFP-HA-TMED10-expressing cells. It is possible that RFP-HA-TMED10 leaks to the cell surface due to the overexpression. Do the authors maybe have fluorescent microscopy images to verify the cellular localization of RFP-HA-TMED10 and nanobody signals?.

12\) In the last paragraph of the subsection "A complex of p24 proteins is required for PrP\* trafficking and degradation", the authors showed that knockdowns of TMED10, TMED2, TMED5 and TMED9 were impaired the PrP\* traffic. The same combination of TMED members has been reported for general transport of GPI-anchored proteins from the ER (J Cell Biol. (2011) 194(1):61-75), suggesting that the TMED subfamily members are utilized not only for exit of misfolded GPI-anchored proteins from the ER, but also for that of folded GPI-anchored proteins. Please refer to it in the manuscript.

13\) Subsection "Resident ER proteins are associated with cell surface PrP\*", first paragraph, (Figure 6B, bottom panels) should be Figure 6A.

Two points were also raised as suggestions (we do *not* see them as essential for submitting a revised manuscript):

1\) In Figure 7I wonder whether surface-exposed FKBP\*-YFP-GPI after Shield1 washout will be degraded if soluble chaperones (or soluble portions of membrane-bound chaperones) are supplied to the medium (i.e. if the presence of chaperones would suffice to trigger degradation)?

2\) In Figure 7, FKBP\*-YFP-GPI was used to show the stability on the cell surface. The reviewer recommends to check whether the FKBP\*-YFP-GPI is also expressed on the cell surface by ER stress using thapsigargin treatment, similar to PrP\*.

10.7554/eLife.46740.021

Author response

> Experimental additions:
>
> 1\) In Figure 1D the authors show complete degradation by 3 hours of PrP\*-GFP in the presence of CHX but in Figure 1E the time lapse only continues until 2 hours (120minutes) with no CHX. It would be important to see the microscopy that correlates with the flow cytometry of Figure 1D (time points until 3 hours +CHX) to ensure that there is no change in trafficking pattern with CHX or at longer times.

As suggested, we have carried out the time lapse microscopy for 3 h in the presence of cycloheximide (CHX) to illustrate that trafficking is not affected, and that overall GFP signal decreases consistent with the flow cytometry experiment. The new experiment is shown in Figure 1E, and the previous experiment has now moved to Figure 3---figure supplement 1, where it can be compared to the analogous experiment in TMED10 knockout cells.

> 2\) Figure 6D exploits the high on rates of the RFP nanobodies for RFP, such that RFP-TMED10 molecules at the cell surface pick up the nanobody, internalise it and the fluorescent label of the nanobody accumulates in the cell and generates a FACS signal. Could the authors expand on the client dependence of this process: Was it enhanced by co-expression of PrP\*? By exposure of the cells to thapsigargin? Was it inhibited by brefeldin A? Have the authors tried to detect PrP\*/thapsigargin dependent exposure of BiP or CNX on the cell surface by FACS?
>
> The claim that PrP\* is accompanied by ER resident proteins to the cell surface is one of this paper\'s most important. Right now the strongest support of this is the RFP-TMED10 expression on the cell surface however in this experiment TMED10 is overexpressed and this can lead to abnormal trafficking of this protein. Hence, any evidence to support further the notion of ER chaperones traveling with clients all the way to the cell surface on their way to degradation would greatly strengthen the manuscript.

We agree with the reviewers that the discovery of ER resident proteins accompanying a misfolded client to the cell surface is the most significant finding of our paper. This conclusion is supported by three independent results using orthogonal approaches: (i) time-resolved analysis of GFP-PrP\* interactions during acute stress shows little or no change in association with endogenous Calnexin and TMED10 (Figure 5D, 5F; Figure 5---figure supplement 1C) despite complete egress from the ER (Figure 1E; Figure 3---figure supplement 1E) and near-quantitative transit through the cell surface (Figure 3B) over this time frame; (ii) selective immunopurification of surface-localised GFP-PrP\* co-purifies endogenous Calnexin and TMED10 (Figure 6B, 6C; Figure 6---figure supplement 1A-1D); (iii) proximity labelling selectively of surface GFP-PrP\* in intact cells labels Calnexin (Figure 6F). In each of these experiments, selectivity is observed for PrP\* over wild type PrP. Therefore, the evidence strongly supports our conclusion that misfolded PrP\* engages ER proteins that retain their interactions all the way to the plasma membrane; we cannot think of an alternative model that matches all of the above results, and none was offered by the reviewers.

The above experiments use GFP-PrP\* (i.e., the substrate) as the handle with which to detect and analyze interacting partners. As rightly pointed out by the reviewers, the 'reverse' experiment of analyzing the interacting partners would be a nice complement to the existing evidence. While one can show that native IPs of TMED10 or calnexin by can co-precipitate PrP\*, the challenge is to analyze ONLY the surface population. We have made several attempts toward this goal, but have faced substantial challenges due to the extremely low proportion of these normally ER-resident proteins on the surface combined with the limitations of available antibodies. As discussed in the text and documented in Figure 6C (and Figure 6---figure supplement 1D), only \~0.5% of cellular Calnexin and TMED10 is engaged with PrP\* on the surface. Monitoring this tiny population requires reagents that bind with exquisitely high affinity and specificity, such as the anti-GFP nanobody that enabled us to detect surface-localised GFP-PrP\*. Unfortunately, labelling with available antibodies against the non-cytosolic domains of endogenous ER resident proteins (Calnexin, TMED10, and BiP) has not provided sufficient signal-to-noise to allow for direct observation of these factors at the surface.

This reagent limitation is why we turned to exogenous RFP-TMED10 (to exploit the high affinity anti-RFP nanobody) expressed in TMED10-knockout cells. As correctly noted by the reviewers, this approach suffers from the potential for overexpression artefacts. In addition to the caveat of possible mislocalisation, overexpression of an ER protein can, in itself, be an ER stressor (Satpute-Krishnan et al., 2014). Thus, under these conditions, cells show a strongly blunted response to additional ER stressors, confounding experiments to analyze stress-dependence of surface RFP-TMED10. We have concluded that to properly monitor TMED10, Calnexin, and other factors, it will be necessary to tag the factor in the genome (so that high affinity nanobodies can be exploited as we did with GFP-PrP\*), verify that the tag does not disrupt either function or trafficking, then perform the analysis. This will be an extensive endeavour for future studies. The anti-RFP Nb uptake by RFP-TMED10 was intended as an initial step toward this aim. Given the caveats of this experiment (and the already strong support for the central conclusion as summarized above), we have opted to remove this experiment, and point out the above limitations in the Discussion (fifth paragraph).

> Textual changes:
>
> 1\) In the Introduction when PrP is first introduced the authors may want to already mention that PrP is a model GPI anchor protein.

We have made this change (Introduction, second paragraph).

> 2\) In the first Results section the authors write GFP-wtPrP -- this \"wt\" denotation is not required nor is it used elsewhere.

We thank the reviewers for spotting this, and have made the appropriate change.

> 3\) In Figure 3---figure supplement 1E -- it would be helpful to the readers to label on the images that they are KO of TMED10

We have made this change.

> 4\) Figure 5B -- it would be helpful to readers if it is labeled on the panel itself that KO refers to KO of TMED10

We have made this change.

> 5\) In Figure 4D the authors arrive to some conclusions about requirements of various TMED family members for PrP\* trafficking based on siRNA knockdown experiments. However, since the non-requirement of some TMEDs is discussed based on the absence of phenotype, the authors should show the effectiveness of knockdown (or wait with the conclusion until showing the supporting interactome data in the next figure).

Because we do not have suitable antibodies to verify all the knockdowns, we have removed the table in Figure 4D and tempered our conclusion in the text about which TMEDs are involved in PrP\* trafficking (subsection "A complex of p24 proteins is required for PrP\* trafficking and degradation", last paragraph). Instead, we simply document that not all TMEDs impact PrP\* trafficking by showing that TMED7 knockdown, verified by immunoblotting, does not have an effect on PrP\* (Figure 4---figure supplement 1E).

> 6\) Figure 4---figure supplement 1A and Figure 6 for all sucrose gradients, a MW standard would be helpful.

This has been added.

> 7\) Figure 5F -- The extended interaction of TMED10 also with GFP-wtPrP: could that be due to the GFP moiety on wtPrP, (slow folding?), can this be checked with wtPrP without a tag?

In Figure 5F, total GFP-PrP was immunoprecipitated using the anti-GFP nanobody, whose binding is strictly dependent on folded GFP. Therefore, we don't think TMED10 association via misfolded GFP is a likely explanation.

> 8\) In Figure 2E to G, the surface levels of GFP-PrP\* were analyzed by AP2 knockdown, expression of Dynamin or brefeldin A treatment. However, since the Nb fluorescence levels are very different between Figure 2E, F and G, it is difficult to judge the results. For example, the fluorescence levels of AP2-KD in Figure 2E is similar to those of control in Figure 2F and G. Please double check this and provide more representative images if possible or just double check the reproducibility.

The experiments in Figure 2E-G are independent experiments performed on different days. Each one is internally controlled and the control cells that are shown in each graph were grown, harvested, and analyzed in parallel with the experimental sample. The numerical values from different experiments are not comparable to each other because the absolute number assigned to nanobody fluorescence is dependent on the model of flow cytometer (we have several), the settings, and calibration. This is why all flow cytometry experiments throughout the study always have the respective controls analyzed at the same time. We have made a note in the Materials and methods section to clarify this point (subsection "Flow cytometry").

> 9\) In Figure 6C, the authors showed that surface PrP\* associates with calnexin and TMED10. As the control, they used PrP and loaded only 5% of the IP fraction. Please elaborate on whether, even if the authors load 100% wild-type PrP samples, the calnexin and TMED10 are not detected in the IP fraction?

The reviewer's concern about loading only 5% of the PrP IP fraction is well taken, so we repeated the experiment in another way. We titrated the amount of nanobody used to label PrP cells in order to achieve the same amount of surface labelling and recovery as PrP\* cells. Consequently, we were able to isolate equal amounts of surface-localized PrP and PrP\*, and demonstrate that calnexin and TMED10 preferentially associate with PrP\*. The approach is explained in detail in the legend for Figure 6C.

If all of the surface PrP and PrP\* is isolated from cells, one recovers \~20-fold more PrP than PrP\* (e.g., Figure 6---figure supplement 1A and 1B). Even under these conditions, the PrP sample contains less calnexin (see stained gels in Figure 6---figure supplement 1A and 1B) and similar amounts of TMED10 (not shown) as the PrP\* sample. Thus, the ratio of associating factor to PrP\* at the cell surface is 20-50 times higher than for PrP. The small proportion of PrP that associates with Calnexin and TMED10 at the surface might be the population that fails to fold during biogenesis at the ER, thereby necessitating sustained interaction with the ER-derived factors as with PrP\*.

> 10\) Similarly, in Figure 6F, did the authors load same amounts of samples in the strep PD fraction? If so, pull downed Nb-APEX was the same level between PrP and PrP\* samples, even if the surface expressions of PrP and PrP\* were quite different. Is it correct?

In Figure 6F, the Nb-APEX was titrated in the PrP condition to achieve equal cell surface labelling to that in the PrP\* condition (as described in the response to the previous comment). This allowed us to examine the neighbouring proteins of an equivalent number of surface APEX molecules on the surface of PrP and PrP\* cells. This is why equal amounts of Nb-APEX was recovered when equal amounts of sample are analyzed on the blot. This is stated in the legend.

> 11\) In Figure 6D, the authors analyzed the internalization of anti-RFP nanobody in RFP-HA-TMED10-expressing cells. It is possible that RFP-HA-TMED10 leaks to the cell surface due to the overexpression. Do the authors maybe have fluorescent microscopy images to verify the cellular localization of RFP-HA-TMED10 and nanobody signals?.

In view of the reviewers' concerns about overexpression of exogenous RFP-TMED10, we have opted to omit Figure 6D until better reagents are available (see detailed reply above).

> 12\) In the last paragraph of the subsection "A complex of p24 proteins is required for PrP\* trafficking and degradation", the authors showed that knockdowns of TMED10, TMED2, TMED5 and TMED9 were impaired the PrP\* traffic. The same combination of TMED members has been reported for general transport of GPI-anchored proteins from the ER (J Cell Biol. (2011) 194(1):61-75), suggesting that the TMED subfamily members are utilized not only for exit of misfolded GPI-anchored proteins from the ER, but also for that of folded GPI-anchored proteins. Please refer to it in the manuscript.

We thank the reviewers for their observation and included this reference.

> 13\) Subsection "Resident ER proteins are associated with cell surface PrP\*", first paragraph, (Figure 6B, bottom panels) should be Figure 6A.

We have made this change.

> Two points were also raised as suggestions (we do not see them as essential for submitting a revised manuscript):
>
> 1\) In Figure 7I wonder whether surface-exposed FKBP\*-YFP-GPI after Shield1 washout will be degraded if soluble chaperones (or soluble portions of membrane-bound chaperones) are supplied to the medium (i.e. if the presence of chaperones would suffice to trigger degradation)?

This is a very interesting suggestion, and one we have considered trying. However, we believe there is still a requirement for some sort of transmembrane factor in order to "communicate" with endocytosis machinery in the cytosol.

> 2\) In Figure 7, FKBP\*-YFP-GPI was used to show the stability on the cell surface. The reviewer recommends to check whether the FKBP\*-YFP-GPI is also expressed on the cell surface by ER stress using thapsigargin treatment, similar to PrP\*.

Figure 7---figure supplement 1A shows extracellular nanobody uptake before (time 0) and after (later time points) thapsigargin treatment without Shield 1. Time 0 represents surface staining because no uptake has been allowed to happen. Similar to PrP\*, thapsigargin promotes nanobody uptake in the absence of Shield1, consistent with FKBP\*-YFP-GPI exiting from the ER and transiently transiting the cell surface en route to degradation. Thus, FKBP\*-YFP-GFP goes to the surface upon thapsigargin treatment similar to PrP\*.
